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(57) 	 ABSTRACT 
An apparatus and method to modify the genetic regulation of 
mammalian tissue, bone, or any combination. The method 
may be comprised of the steps of tuning at least one prede-
termined profile associated with at least one time-varying 
stimulation field thereby resulting in at least one tuned time-
varying stimulation field comprised of at least one tuned 
predetermined profile, wherein said at least one tuned prede-
termined profile is comprised of a plurality of tuned prede-
termined figures of merit and is controllable through at least 
one of said plurality of tuned predetermined figures of merit, 
wherein said plurality of predetermined tuned figures of merit 
is comprised of a tuned B-Field magnitude, tuned rising slew 
rate, tuned rise time, tuned falling slew rate, tuned fall time, 
tuned frequency, tuned wavelength, and tuned duty cycle; and 
exposing mammalian chondrocytes, osteoblasts, osteocytes, 
osteoclasts, nucleus pulposus, associated tissue, or any com-
bination to said at least one tuned time-varying stimulation 
field comprised of said at least one tuned predetermined pro-
file for a predetermined tuned exposure time or plurality of 
tuned exposure time sequences. 
20 Claims, 7 Drawing Sheets 
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50 
Tuning at least one predetermined profile for at least one time- 
varying stimulation field. 
12 	 Controlling at least one tuned time-varying stimulation field to 
produce at least one tuned predetermined profile. 
Exposing mammalian chondrocytes, osteoblasts, osteocytes, 
11 
	
	
osteoclasts, nucleus pulposus, associated tissue, or any 
combination to at least one tuned time-varying stimulation 
field comprised of at least one tuned predetermined profile for 
a predetermined tuned exposure time or plurality of tuned 
exposure time sequences. 
FIG. 7 
11 
Exposing mammalian 
chondrocytes, osteoblasts, 	 ] 
	 I [ Providing a stimulation field generator 
osteocytes, osteoclasts, apparatus in proximate spatial relationship 
nucleus pulposus, associated to mammalian chondrocytes, osteoblasts, 
18 
tissue, or any combination to osteocytes, osteoclasts, nucleus pulposus, 
at least one tuned time- associated tissue, or any combination. 
varying stimulation field 
comprised of at least one 
tuned predetermined profile Generating a tuned time-varying 19 
for a predetermined tuned 
stimulation field using said stimulation field 
exposure time or plurality of 
generator apparatus. 
tuned exposure time. 
FIG. 8 
U.S. Patent 	 Aug. 5, 2014 	 Sheet 6 of 7 	 US 8,795,147 B1 
51 
Tuning at least one 
tuned predetermined 
profile for at least one 
tuned time-varying 
stimulation field. 
Providing at feast one set of cellular 
samples in at least one rotating waft vessel. 
Exposing said at least one set of cellular 
samples to at feast one experimental time-
varying stimulation field comprising at least 
one experimental predetermined profile. 
Conducting at least one gene expression 
analyses to said at least one set of cellular 
samples. 
Analyzing the genetic anabolic and catabolic 
effects from the results of said at least one 
gene expression analyses. 
Generating at least one conclusion from 
said step of analyzing. 
1 
52 
53 
54 
55 
65 
Does the Adjusting said a 	 least one 
at least one 
conclusion meet experimental predetermined 
predetermined profile based on said at least 
criteria? 	 No one conclusion. 
Yes Y 
 
56 
Selecting said at least one tuned time-
varying stimulation field comprised o` said 
at least one tuned predetermined profile 
for said predetermined tuned exposure 
time or said plurality of tuned exposure 
time sequences. 
57 
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54 
Analyzing the genetic 
anabolic and catabolic 
effects from the results of 
said at least one gene 
expression analyses. 
Selecting a predetermined set of genes or 
gene families. 
Calculating a fold change for each gene in 
said set of genes from the results of said at 
least one gene expression 
Determining if each of said fold change is 
consistent with up-regulation or down-
regulation for said each gene. 
58 
59 
60 
Determining if each of said fold change is 
consistent with up-regulation or down-
regulation for said each gene. 
FIG. 10 
Establishing a relative value for each of said 
anabolic or catabolic effect on said up- 
55 ~\ 	 regulation or down-regulation for said each 
gene. 
Generating at least one 	 Comparing each of said relative value in 
conclusion from said step 	
combination. 	
63 
of analyzing. 
Selecting a conclusion comprised of either a 
substantive 	 net 	 anabolic 	 effect, 	 a 
substantive net catabolic effect, a net 
	 64 
anabolic effect, a net catabolic effect, or no 
determinative effect. 
61 
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MODIFYING THE GENETIC REGULATION 
OF BONE AND CARTILAGE CELLS AND 
ASSOCIATED TISSUE BY EMF 
STIMULATION FIELDS AND USES THEREOF 
ORIGIN OF THE INVENTION 
The invention described herein was made by employees of 
the United States Government and may be manufactured and 
used by or for the Government of the United States of 10 
America for governmental purposes without the payment of 
any royalties thereon or therefor. 
BACKGROUND OF THE INVENTION 
15 
1. Field of the Innovation 
The present innovation relates generally to the fields of 
biophysics, bioelectromechanics, tissue regeneration, tissue 
culture, and neurophysiology. More specifically, the present 
innovation relates to the use of an electromagnetic field, and 20 
preferably, a time-varying magnetic field, for modifying, 
potentiating or controlling the growth and specific genetic 
expression of biological cells and tissue, such as mammalian 
tissue. More specifically, the present innovation relates to the 
use of a noninvasive method and apparatus comprising rela- 25 
tively low frequency magnetic fields for modifying the 
genetic regulation of mammalian chondrocytes, osteoblasts, 
osteocytes, osteoclasts, nucleus pulposus, associated tissue, 
or any combination. 
2. Background and Related Art 	 30 
Cartilage 
Cartilage is a type of dense connective tissue existing 
within many joints. It is composed of specialized cells called 
chondrocytes that produce a large amount of extracellular or 
cartilaginous matrix comprised of actin and collagen fibers, 35 
proteoglycans, glycosaminoglycans, and elastin fibers. 
Chondrocytes are the only cells found in cartilage. Cartilage 
is classified in three types, elastic cartilage, hyaline cartilage, 
and fibrocartilage. Cartilage is found in many areas in a mam-
malian body, including the articular surface of the bones, the 40 
rib cage, the ear, the nose, the bronchial tubes and the inter-
vertebral discs. Its mechanical properties are intermediate 
between bone and dense connective tissue like tendon. (Car-
tilage, 2010) 
Unlike other connective tissues, cartilage does not contain 45 
blood vessels or is referred to as avascular. The chondrocytes 
are fed by diffusion, helped by the pumping action generated 
by compression of the articular cartilage or flexion of the 
elastic cartilage. Thus, compared to other connective tissues, 
cartilage grows and repairs more slowly. (Cartilage, 2010) 50 
There are several diseases which can affect the cartilage. 
Chondrodystrophies are a group of diseases characterized by 
disturbance of growth and subsequent ossification of carti-
lage. Osteoarthritis (OA) is a common disease affecting car-
tilage. Osteoarthritis, also known as a degenerative joint dis- 55 
ease, is a group of mechanical abnormalities involving 
degradation of joints, including articular cartilage and sub-
chondral bone. The cartilage covering bones (articular carti-
lage) is thinned, eventually completely worn out, resulting in 
a "bone against bone" joint, reduced motion, and pain. 60 
Osteoarthritis is very common, affects the joints exposed to 
high stress, and is therefore considered the result of"wear and 
tear" rather than a true disease. The usual symptoms are 
stiffness, limitation of motion, and pain. Osteoarthritis is the 
most common form of arthritis, and prevalence rates increase 65 
markedly with age. It has been shown that elderly patients 
with self-reported osteoarthritis visit doctors twice as fre- 
quently as their unaffected peers. Such patients also experi-
ence more days of restricted activity and bed confinement 
compared to others in their age group. (Cartilage, 2010) 
Cartilage has limited repair capabilities, because chondro-
cytes are bound in lacunae, they cannot migrate to damaged 
areas. Therefore, if damaged, cartilage is difficult to heal. 
Also, because hyaline cartilage does not have a blood supply, 
the deposition of new cartilaginous matrix is slow. Damaged 
hyaline cartilage is usually replaced by fibrocartilage scar 
tissue. (Cartilage, 2010) 
Acetaminophen/paracetamol is generally used as a first 
line treatment and anti-inflammatory drugs (NSAIDs) are 
only recommended as add on therapy if pain relief is not 
sufficient. This is due to greater safety of acetaminophen as 
opposed to NSAIDS. In addition, to these treatments, several 
cartilage regeneration techniques have been developed. 
These techniques include the following: (1) debridement or 
abrasion surgeon arthroscopically removes loose cartilage 
which causes bleeding at the bone surface and growth of 
fibrocartilage (fibrous cartilage or scar tissue) but the fibro-
cartilage may not be strong enough; (2) microfracture sur-
geon arthroscopically clears the affected area and makes sev-
eral perforations in the bone to stimulate bleeding and growth 
of fibrocartilage; (3) mosaicpiasty or osteochondral autograft 
transplantation surgery surgeon removes a plug of bone 
with cartilage covering from a healthy area of the joint and 
transplants it to the damaged area; (4) periosteal flap—sur-
geon removes a portion of the periosteum (connective tissue 
covering all bones) from shin and transplants it to the area of 
cartilage damage; (5) autologous chondrocyte implanta-
tion—surgeon arthroscopically removes small portion of car-
tilage from knee; tissue is sent to a lab to be cultured; second 
surgery required so lab-grown cells can be implanted at the 
site of the damaged cartilage; and (6) osteochondral 
allografts donor bone is used to repair the damaged carti-
lage. These procedures yield mixed and often inconsistent 
results. There are still many questions that plague attempts at 
cartilage regeneration. There is a need to find definitive 
answers and to develop procedures that relieve arthritis symp-
toms and produce a durable replacement for damaged carti-
lage. 
Bone 
Bones are rigid organs that form part of the endoskeleton of 
vertebrates. Bones function to move, support, and protect the 
various organs of the body, produce red and white blood cells 
and store minerals. Bone tissue is a type of dense connective 
tissue. Bones comprise an organic component of cells and 
matrix as well as an inorganic ormineral component. Because 
bones come in a variety of shapes and have a complex internal 
and external structure they are lightweight, yet strong and 
hard, in addition to fulfilling their many other functions. One 
of the types of tissue that makes up bone is the mineralized 
osseous tissue, also called bone tissue, which gives it rigidity 
and a honeycomb-like three-dimensional internal structure. 
Other types of tissue found in bones include marrow, endos-
teum and periosteum, nerves, blood vessels and cartilage. 
(Bone, 2010) 
There are several types of cells constituting the bone. For 
example, osteoblasts are mononucleate bone-forming cells 
that descend from osteoprogenitor cells. They are located on 
the surface of osteoid seams and make a protein mixture 
known as osteoid, which mineralizes to become bone. 
Osteoid is primarily composed of Type I collagen. Osteo-
blasts also manufacture hormones, such as prostaglandins, to 
act on the bone itself. They robustly produce alkaline phos-
phatase, an enzyme that has a role in the mineralization of 
bone, as well as many matrix proteins. Osteoblasts are the 
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immature bone cells. In addition, bone lining cells are essen-
tially inactive osteoblasts. They cover all of the available bone 
surface and function as a barrier for certain ions. Still further, 
osteocytes originate from osteoblasts that have migrated into 
and become trapped and surrounded by bone matrix that they 
themselves produce. The spaces they occupy are known as 
lacunae. Osteocytes have many processes that reach out to 
meet osteoblasts and other osteocytes probably for the pur-
poses of communication. Their functions include to varying 
degrees: formation of bone, matrix maintenance and calcium 
homeostasis. They have also been shown to act as mechano-
sensory receptors regulating the bone's response to stress 
and mechanical load. They are mature bone cells. Finally, 
osteoclasts, a form of macrophage, are the cells responsible 
for bone resorption (remodeling of bone to reduce its vol-
ume). Osteoclasts are large, multinucleated cells located on 
bone surfaces in what are called Howship's lacunae orresorp-
tion pits. These lacunae, or resorption pits, are left behind 
after the breakdown of the bone surface. Because the osteo-
clasts are derived from a monocyte stem-cell lineage, they are 
equipped with phagocytic like mechanisms similar to circu-
lating macrophages. Osteoclasts mature, migrate, or both to 
discrete bone surfaces. Upon arrival, active enzymes, such as 
tartrate resistant acid phosphatase, are secreted against the 
mineral substrate. (Bone, 2010) 
In the disease commonly known as osteoporosis, bone 
demineralizes and becomes abnormally rarefied. The cells 
and matrix of a bone comprise a framework of collagenous 
fibers which is impregnated with the mineral component of 
calcium phosphate (-85%) and calcium carbonate (-10%) 
which imparts rigidity to the bone. While osteoporosis is 
generally thought of as afflicting the elderly, certain types of 
osteoporosis may affect persons of all ages whose bones are 
not subject to functional stress. In such cases, patients may 
experience a significant loss of cortical and cancellous or 
trabecular bone during prolonged periods of immobilization. 
Elderly patients are known to experience bone loss due to 
disuse when immobilized after fracture of a bone, which may 
ultimately lead to a secondary fracture in an already 
osteoporotic skeleton. Diminished bone density may lead to 
vertebrae collapse, fractures of hips, lower arms, wrists, 
ankles as well as incapacitating pains. 
Current therapies comprise invasive procedures (e.g. sur-
gery or drug administration) as opposed to the described 
innovation which is a non-invasive procedure. Alternative 
nonsurgical therapies for such diseases include electrical 
bone growth stimulation comprised of electric and magnetic 
field therapies. However these therapies are moderately inva-
sive as they rely on either skin contact or insertion of probes/ 
electrodes into the tissue to achieve the desired results. 
Nucleus Pulposus 
Nucleus pulposus is the jelly-like substance in the middle 
of the spinal disc. It functions to distribute hydraulic pressure 
in all directions within each disc under compressive loads. 
The nucleus pulposus comprises disc chondrocytes (as 
opposed to articular chondrocytes), collagen fibrils, and pro-
teoglycan aggrecans that have hyaluronic long chains which 
attract water. Attached to each hyaluronic chain are side 
chains of chondroitin sulfate and keratan sulfate. (Nucleus 
pulposus, 2008) 
Electric and Magnetic Fields 
An electric field is a property that describes the space that 
surrounds electrically charged particles. Electric fields are 
created by differences in electric potential or voltage: i.e., the 
higher the voltage, the stronger will be the resultant electric 
field. In contrast, magnetic fields that are generated electro-
magnetically are created when electric current flows: i.e., the 
greater the current, the stronger the magnetic field. An electric 
field will exist even when there is no current flowing. In 
contrast, a magnetic field generated electromagnetically will 
not exist when there is no current. If current does flow, the 
5 strength of the magnetic field that is generated electromag-
netically will vary with power consumption but the electric 
field strength will be constant. Resultant forces are related to 
both electric and magnetic fields. The force associated with 
an electric field depends on a stationary or static charge. 
to Conversely, the force exerted on a charged particle associated 
with a magnetic field (i.e., Lorentz force) depends on a mov-
ing charge. Further, electric and magnetic fields are not 
entirely mutually exclusive. For example, charged particles 
15 do not only produce electric fields. As charges move, they 
generate magnetic fields, and if the magnetic field changes, 
the change in said magnetic field will generate electric fields. 
Thus weak metals (ions) such as CA2+, K+, Li+, and Mgt+ 
are all subject to modulation or resonance effect and can be 
20 made to move sub-cellularly due to magnetic flux. Stated 
differently, a changing magnetic field gives rise to an electric 
field. In nature lightning is an example of an atmospheric 
electrical discharge that creates an attendant magnetic field. 
Electrical Stimulation Therapies 
25 	 Electrical stimulation therapies include: capacitive cou- 
pling (CC); and direct current (DC) or direct coupling. The 
original basis for forms of electric stimulation therapy was the 
observation that physical stress on bone causes the appear-
ance of tiny electric currents (i.e., a piezo-electric effect) that, 
3o along with mechanical strain, were thought to be the mecha-
nisms underlying transduction of the physical stresses (com-
pression and tension) into an electrical signal that promotes 
bone formation. CC relies on an electric field that is generally 
generated by 2 capacitive plates or electrodes placed on a 
35 patient's skin on opposite ends of a region of interest to apply 
electrical stimulation in the region of interest. DC-based 
therapies require the placement of opposing electrodes in 
direct contact with the skin surface surrounding the tissue of 
interest (Trock, 2000) and generally involve implantation of 
40 the electrodes. The region of interest is stimulated by a con-
stant direct current. 
Magnetic Field Therapies 
Magnetic field therapies include: time-varying magnetic 
field (TVMF) therapies including pulsed electromagnetic 
45 field(PEMF)therapies. The general use oftime-varyingmag-
netic fields to stimulate the growth of cells has been previ-
ously disclosed in the related art. It has been theorized that the 
piezo-electric properties in human tissue such as bone and 
cartilage forms the basis for regulating bone and cartilage 
50 formation. Specifically, because a magnetic field imposes a 
force on magnetic particles and moving electrically charged 
particles, the magnetic field forces simulate physical stress in 
human tissue thereby resulting in small, induced currents 
(Faraday currents) in the tissue's highly conductive extracel- 
55 lular fluid. In general, time-varying magnetic field therapies 
involve the use of coils to electrically generate a magnetic 
field. PEMFs are considered a subset of time-varying mag-
netic field therapies and are generally associated with pulses 
or bursts in its waveforms. Resultant waveforms used in 
60 PEMF therapies can be substantially monophasic, substan-
tially biphasic, substantially square, sinusoidal, or substan-
tially triangular. Further, PEMF therapies are generally com-
prised of frequencies on the lower end of the electromagnetic 
spectrum such as from 6-500 Hz. Further, waveforms used in 
65 PEMF therapies generally have high rising and falling slew 
rates on the order of Tesla/sec, thereby promoting said pulses 
or bursts. 
US 8,795,147 B 1 
5 
In U.S. Pat. No. 7,179,217 an apparatus for enhancing 
tissue repair in mammals is disclosed. The disclosed appara-
tus comprises: a sleeve for encircling a portion of a mamma-
lian body part, said sleeve comprising an electrically conduc-
tive coil capable of generating a magnetic field when an 5 
electrical current is applied thereto, means for supporting the 
sleeve on the mammalian body part; and a means for supply-
ing the electrically conductive coil with a square wave time-
varying electrical current sufficient to create a time-varying 
magnetic force of from approximately 0.05 G to 0.5 G within io 
the interior of the coil in order that when the sleeve is placed 
on a mammalian body part and the time-varying magnetic 
force of from approximately 0.05 G to 0.5 G is generated on 
the mammalian body part for an extended period of time, 
tissue regeneration within the mammalian body part is 15 
increased to a rate in excess of the normal tissue regeneration 
rate that would occur without application of the time-varying 
magnetic force. The electrically conductive coil is preferably 
a ferromagnetic material, such as wire, with approximately 
ten windings per inch. The sleeve can be placed on a body 20 
part, e.g. an arm or a leg, of the mammal and the body part 
exposed to the 0.05 G to 0.5 G time-varying magnetic force 
for an extended period of time to enhance tissue repair, such 
increasing the healing rate of bone fracture repair or increased 
healing rate of ulcerated skin. It is preferable that the treated 25 
mammal is provided an increased level of calcium ions (Ca+ 
or Ca++) during the application of the time-varying magnetic 
force. 
Anabolic and Catabolic Gene Expressions 
Scientists have traditionally classified hormones into two 30 
categories: anabolic or catabolic, depending on which part of 
metabolism they stimulate. The traditional anabolic hor-
mones are the anabolic steroids, which stimulate protein syn-
thesis and muscle growth. Conversely, the traditional cata-
bolic hormones are adrenaline (and other catecholamines). In 35 
recent decades, many more hormones with at least some 
effects have been discovered, including cytokines or para-
crine and autocrine factors which are the products of genomic 
up or down regulations. The combination of anabolic and 
catabolic effects is by no means the sum and total of the 40 
genomic capacity to stimulate reconstructive changes within 
the physiology. Further specific genes and some molecules 
work in concert with each other or in gene cascades (chaper-
ones) which facilitate the end goal of tissue remodeling, with 
processes such as glucose metabolism fluctuating to match an 45 
animal's normal periods of activity throughout the day (Ram-
sey, Marcheva, Kohsaka, & Bass, 2007). 
Similarly, known biomolecules such as vitamins are 
extremely useful in perpetuating the process of normal carti-
lage and bone maintenance. Two such molecules are Vitamin 50 
(specifically D3) and Vitamin K. The actions of these vita-
mins are known to a degree in relation to normal mammalian 
(specifically human) physiology (Ishikawa, 2006), (Atkins, 
2009), (Koshihara, 1997). The inventors postulate that due to 
the facilitated stimulation of important gene expressions 55 
(specifically osteocalcin up-regulation which was unantici-
pated as part of the responding cascade) that addition of 
increased concentrations of these two vitamins during treat-
ment of the affected area (ROI) in any outlined regime or 
matrix will further enhance and accelerate the formation of 60 
new bone and differentiate the expression of bone from car-
tilage in the subject tissue as mineralization will produce 
bone and not cartilage. Osteocalcin is known to be a biologi-
cal cofactor which when exposed to increased amounts of 
Vitamin K leads to mineralization of new bone. Thus, addi- 65 
tion of Vitamin D3 in concentrations from 200-1000 IU daily 
and Vitamin K from about 50 to about 2000 mg daily will  
6 
further facilitate the regeneration (anabolic effects) of bone 
and differentiate bone from cartilage formation. Additionally, 
osteocalcin is also tied to energy generation (needed espe-
cially for rapid cell growth) by modulating the production of 
insulin. 
Anabolism is the set of metabolic pathways or genomic and 
protein responses that construct molecules from smaller units 
(de Bolster, 1997). These reactions require an energy system 
which in the case of cells is derived from other genomic 
responses in the breakdown of energy "packets" in the cell. 
One way of categorizing metabolic processes, whether at the 
cellular, organ or organism level is as anabolic or as catabolic, 
which is the opposite of anabolic. Anabolism is powered by 
catabolism, where large molecules are broken down into 
smaller parts and then used up in oxidative metabolism of 
respiration. Many if not all anabolic processes are powered by 
adenosine triphosphate (ATP), adenosine diphosphate (ADP) 
or adenosine monophosphate (AMP) (Nicholls & Ferguson, 
2002). Anabolic processes are generally associated with 
"building up" or regeneration of organs and tissues. These 
processes produce growth and differentiation of cells and 
increase in organ or body size, a process that involves manu-
facture and production of complex building blocks known as 
molecules. Classic examples of anabolic processes include 
the regeneration, growth of cartilage, growth and mineraliza-
tion of bone and increases in muscle mass and complexity. In 
genomic terms and for the purposes herein, "anabolic" will be 
associated with the building of tissue or the regeneration of 
tissue from an organic perspective. 
Catabolism is the set of pathways that break down mol-
ecules into smaller units and release energy (de Bolster, 
1997). In catabolism, large molecules such as nucleic acids, 
proteins, polysaccharides, and lipids, and are broken down 
into smaller units such as amino acids, nucleotides, monosac-
charides, and fatty acids, respectively. As molecules such as 
polysaccharides, proteins, and nucleic acids are made from 
long chains of these small monomer units, the large mol-
ecules are called polymers. Cells use the monomers released 
from breaking down polymers to either construct new poly-
mer molecules, or degrade the monomers further to simple 
waste products, releasing energy. Cellular wastes include lac-
tic acid, acetic acid, carbon dioxide, ammonia, and urea 
which require scavenger molecules to "clean up" so as not to 
pollute the organic system. Creation of these wastes is a 
function of the oxidation process involving a release of 
chemical energy, some of which is lost as heat, but the rest of 
which is used to drive the synthesis of adenosine triphosphate 
(ATP). This molecule acts as a way for the cell and thus the 
organism to transfer the energy released by catabolism to the 
energy-requiring reactions (genomic functions) that make up 
anabolism or construction of the tissue. These anabolic pro-
cesses are controlledby genomic cascades which"cooperate" 
to achieve the desired end result; that of formation of new 
tissue. This catabolism provides the chemical energy and 
genomic instruction necessary for the maintenance and 
growth of cells, which can be referred to as a reparative 
function. In genomic terms, catabolism is the reorganization 
or destruction of tissue such as one sees in osteoarthritis or 
osteoporosis. Thus the process of bone remodeling and osteo-
clastogenesis are examples of a catabolic event driven by 
genes specifically associated with the process. For the pur-
poses of herein, "catabolic" will be associated with a repara-
tive function and specifically, the breakdown, reorganization, 
or the degeneration of tissue from an organic perspective. 
Currently, full advantage is not being taken of the use of 
these biophysical and electrical stimuli in the health care 
professions, due to lack of knowledge and education in this 
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field. However, as the underlying mechanisms at the molecu-
lar and cellular level become understood, it is hoped that these 
stimuli will be better defined and utilized, and as a result, 
medical instrumentation using this medical technology will 
therefore become more widely implemented in the clinical 5 
and out-patient setting. Currently, the related art primarily 
depends on frequency and B-Field magnitude associated with 
an electromagnetic field waveform for the stimulated growth 
of biological cells and associated tissue. In fact, related art 
publications indicate that a B-Field magnitude is the primary 10 
control variable for affecting biological cell and tissue 
growth. At some point, the B-field magnitude's effect 
becomes more of a thermal effect as compared to a physical 
force imparted at the cellular level. For example any magnetic 
field greater than 30 kHz falls into the radio frequency range 15 
and is known to result in thermal heating effects at the sub-
cellular level. The related art is deficient in discovery of a 
specific stimulation field profile necessary for up-regulating 
and down-regulating specific genes, wherein said profile is 
comprised of not only frequency and B-Field magnitude, but 20 
also waveform shape, rise time, rising slew rate, fall time, 
falling slew rate, duty cycle, dwell time, time of exposure, and 
other possible factors. The therapeutic implications of the 
discovery of specific profiles associated with stimulating spe-
cific genes will be explained herein. Thus, it would be desir- 25 
able to provide an apparatus and method of use which would 
promote the stimulation of specific genes by a specific stimu-
lation field of predetermined profile. 
SUMMARY OF THE INVENTION 	 30 
The present invention relates to a system and method to 
modifying the genetic regulation of mammalian chondro-
cytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus, 
associated tissue, or any combination. There are multiple 35 
embodiments with respect to what comprises "associated 
tissue". For example, associated tissue may comprise carti-
laginous tissue, osseous tissue, connective tissue, cancellous 
tissue, tendon and muscle, or any combination, etc. More 
specifically, the act of modifying may be comprised of pro- 40 
moting the retention, repair of and reduction of compromised 
cartilage, bone, and associated tissue in a mammalian system 
by preferential stimulation of the aforementioned cell types in 
the mammalian physiology in a specific order or sequence. A 
stimulation field generator may be used to deliver a tuned 45 
time-varying stimulation field profile of predetermined per-
formance characteristics or Figures of Merit (FOM) to the 
targeted tissue for a predetermined tuned exposure time or 
plurality of tuned exposure time sequences wherein said 
FOMs may comprise B-Field magnitude, frequency, wave- 50 
length, rising slew rate, falling slew rate, rise time, fall time, 
and duty cycle(s). The apparatus may include several com-
ponents comprising: 1) a power source, 2) control compo-
nent, and 3) a transmission component. The power source 
supplies the electricity necessary to produce an electromag- 55 
netically generated time-varying stimulation field of prede-
termined profile that is controlled and governedby the control 
component of the apparatus wherein said time-varying stimu-
lation field is induced to a target tissue or region of interest 
(ROI) by a transmission component. The transmission com- 60 
ponent may take the embodiment of standard transmission 
antennae, magnetic coils, a complexed array that consists of 
multiple coils, antennae to deliver the correct magnetic field 
to the ROI in the proper field density, or any combination. In 
an embodiment, the apparatus delivers a tuned time-varying 65 
stimulation field comprising at least one tuned predetermined 
profile to preferentially stimulate (up-regulate, down-regu- 
8 
late, or a combination of both) the biochemical cellular and 
sub-cellular molecular responses to trigger the activation of 
known mammalian genes responsible for the regeneration, 
restoration, repair, maintenance, or any combination of car-
tilage, bone, or both. 
Accordingly, it is an object of the present innovation to 
provide an apparatus for biomedical therapeutic applications 
based on the application of time-varying magnetic fields, and 
more particularly to TVMFs produced in a device which 
utilizes a tuned electrical signal capable producing a tuned 
predetermined time-varying stimulation field comprised of at 
least one tuned predetermined profile at a treatment site for 
cartilage, bone, and soft tissue therapy. 
It is another object of the present innovation to provide a 
multi-functional, modular device using wire coils that create 
a tuned predetermined time-varying stimulation field of at 
least one tuned predetermined profile designed for penetra-
tion into cartilage, bone, associated tissue, or any combina-
tion for the treatment of osteoarthritis, fractures, osteoporo-
sis, and the like. 
It is a further object of the invention to provide at least one 
tuned electrical signal based on frequency, amplitude, rise 
time, rising slew rate, fall time, falling slew rate, duty cycle, 
dwell cycle(s), or any combination to a stimulation field gen-
erator apparatus in order to generate and emit a tuned time-
varying stimulation field of at least one tuned predetermined 
profile that will result in modifying the genetic regulation of 
the aforementioned mammalian cells. 
It is yet another object of the invention to provide time-
varying magnetic field neuromuscular stimulation utilizing a 
predetermined time-varying stimulation field for reducing 
muscle atrophy as a countermeasure to body unloading 
effects. 
In an embodiment, the apparatus may emit and deliver to 
the target area or tissue a substantially square wave between 
about 9 Hz to about 200 Hz; with a rise time between about 
125 µs to about 1 ms; a rising slew rate of between about 2.0 
kG/s to about 50.0 kG/s; a fall time between about 125 µs to 
1 ms; a falling slew rate of between about 2.0 kG/s to about 
500.0 kG/s, or any combination. Additionally, the apparatus 
may operate on a duty cycle of between about 65% to about 
80% (and a subsequent dwell time of between about 35% to 
about 20%, respectively). Still further, the apparatus may 
operate for a predetermined tuned exposure time from about 
1 hour to about 1200 hours in a continuous manner or based 
on a predetermined time schedule. Deviations from these 
FOMs may elicit deferential responses with regard to mam-
malian cells, ion transport, and thus genetic and protein 
expression. 
In an embodiment, the innovation is a method comprising 
the steps of positioning an apparatus in a predetermined 
proximate spatial relationship to a region of interest compris-
ing damaged chondrocytes, osteoblasts, osteocytes, osteo-
clasts, nucleus pulposus, or any combination, wherein said 
apparatus is capable of producing a time-varying stimulation 
field; generating a predetermined time-varying stimulation 
field in the form of a substantially square waveform with a 
B-Field magnitude from about 0.6 G to about 50 G, a fre-
quency from about 9 Hz to about 200 Hz, a rise time of from 
about 0.75 ms to about 1 ms, rising slew rate from about 2.0 
kG/s to about 20.0 kG/s, a fall time from about 125 µs to about 
300 µs, a falling slew rate from about 5.0 kG/s to about 50.0 
kG/s, and a duty cycle from about 65% to about 80%, and 
wherein said stimulation field promotes the growth of chon-
drocytes, osteoblasts, osteocytes, osteoclasts, nucleus pulpo-
sus, or any combination. 
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having an electric charge, q, and moving in said B-field with 
a velocity, v, experiences a physical force. Further, as used in 
this paper, a "region of interest" is defined as an area targeted 
to be exposed to a stimulation field. A region of interest can 
5 be, for example; a rotating wall vessel containing biological 
materials or a predetermined area on a patient's body. Still 
further, as used in paper, a "profile" refers to a waveform. In 
addition, "figures of merit" refer to measurable performance 
characteristics or values. Still further, "anabolic" refers to the 
to building of tissue orthe regeneration of tissue from an organic 
perspective. "Catabolic" refers to a reparative function and 
specifically, the breakdown, reorganization, or the degenera-
tion of tissue from an organic perspective. HCH as used 
herein refers to human chondrocytes. HOB as used herein 
refers to human osteoblasts. As used herein, NOR refers to no 
15 or zero differential regulation. As used herein, NRF refers to 
no regulated effect. As used herein in the claim(s), when used 
in conjunction with the word "comprising", the words "a" or 
"an" mean one or more. 
So that the matter in which the above-recited features, 
20 advantages and objects of the invention, as well as others that 
will become clear, are attained and can be understood in 
detail, more particular descriptions of the invention briefly 
summarized above may be had by reference to certain 
embodiments thereof that are illustrated in the appended 
25 drawings. These drawings form a part of the specification. It 
is to be noted, however, that the appended drawings illustrate 
preferred embodiments of the invention and therefore are not 
to be considered limiting in their scope. 
FIG. 1 depicts an exemplary stimulation field profile of a 
30 
substantially biphasic, square waveform. 
FIG. 2 depicts an exemplary stimulation field profile of a 
substantially monophasic, delta waveform. 
FIG. 3 illustrates an exemplary stimulation field generator 
apparatus. 
FIG. 4 illustrates an exemplary rotating wall vessel. 
35 FIG. 5 illustrates an exemplary rotating wall vessel inte-
grated with an exemplary stimulation field generator appara-
tus. 
FIG. 6 illustrates an exemplary stimulation field generator 
apparatus in the form of a sleeve wherein said stimulation 
40 field generator apparatus delivers a magnetic field of prede-
termined profile to a region of interest on a mammalian physi-
ology. 
FIG. 7 depicts a flowchart of a method to modify the 
genetic regulation of mammalian tissue, bone, or any combi- 
45 nation comprising the steps of: exposing said mammalian 
chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus 
pulposus, associated tissue, or any combination to at least one 
tuned time-varying stimulation field. 
FIG. 8 depicts a flowchart of sub-steps associated with a 
50 step of exposing mammalian chondrocytes, osteoblasts, 
osteocytes, osteoclasts, nucleus pulposus, associated tissue, 
or any combination to at least one tuned time-varying stimu-
lation field. 
FIG. 9 depicts a flowchart of sub-steps associated with a 
55 step of tuning at least one tuned predetermined profile for at 
least one tuned time-varying stimulation field. 
FIG. 10 depicts a flowchart of sub-steps associated with a 
step of analyzing genetic anabolic and catabolic effects from 
the results of at least one gene expression analyses. 
60 FIG. 11 depicts a flowchart of sub-steps associated with a 
step of generating at least one conclusion from a step of 
analyzing. 
9 
In an embodiment, the innovation is a method comprising 
the steps of providing an apparatus comprising a power 
source, control component, and a transmission component; 
positioning a region of interest comprising damaged chron-
drocytes, osteoblasts, osteocytes, osteoclasts, nucleus pulpo-
sus, or any combination in proximate spatial relationship to 
said apparatus; operating said apparatus to generate time-
varying stimulation filed comprised of a substantially square 
wave with a frequency from about 9 Hz to about 200 Hz, a rise 
time of from about 0.75 ms to about 1 ms, rising slew rate 
from about 2.0 kG/s to about 20.0 kG/s, a fall time from about 
125 µs to about 300 µs, and a falling slew rate from about 5.0 
kG/s to about 50.0 kG/s, wherein the duty cycle of said square 
wave is from about 65% to about 80%, wherein the operation 
of said apparatus produces said time-varying stimulation 
field, and wherein the stimulation field promotes the growth 
of chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus 
pulposus, or any combination. With particular reference to 
FIG. 6, in another embodiment, power source, control com-
ponent, transmission component, or any combination is 
incorporated in a sleeve 20 (such as for example, described in 
U.S. Pat. No. 7,179,217 (Goodwin & Parker, 2007)), wherein 
the power source, control component, and transmission com-
ponent are operably connected to each other. The sleeve is 
capable of wrapping around a ROI 21, such as a body part or 
an appendage of a mammalian physiology and is capable of 
delivering a magnetic field 34 to said ROI. 
In an embodiment, a pulsed stimulation field of predeter-
mined profile may be used in combination with (either seri-
ally or in parallel) a time-varying stimulation field of prede-
termined profile for determining differential matrix signaling 
for accomplishing various therapeutic applications. In 
another embodiment, the control component controls prede-
termined characteristics of one or more fields. In still another 
embodiment, the control component is comprised of a con-
ductor, an amplifier, or both. 
In an embodiment, the stimulation field is comprised of a 
magnetic field of a predetermined profile capable of accom-
plishing CA2+ ionic transport modulation for mammalian 
chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus 
pulposus, associated tissues, or any combination. In another 
embodiment, the stimulation field is comprised of a magnetic 
field of a predetermined profile capable of modifying the 
genetic regulation of mammalian chondrocytes, osteoblasts, 
osteocytes, osteoclasts, nucleus pulposus, associated tissue, 
or any combination. In still another embodiment, the stimu-
lation field is capable of producing or suppressing specific 
biomolecules that are associated with and necessary and 
responsible for the growth, retention, regeneration and repair 
of chondrocytes, osteoblasts, osteoclasts, osteocytes, and 
nucleus pulposus. 
In an embodiment, the predetermined time-varying simu-
lation field is capable of modifying the genetic regulation of 
mammalian chondrocytes, osteoblasts, osteocytes, osteo-
clasts, nucleus pulposus, associated tissues, or any combina-
tion to increase the growth rate of these cells and tissues 
greater than the normal physiological rates of growth. In 
another embodiment, the predetermined time-varying stimu-
lation field is capable of being regulated to enhance the 
growth, retention, restoration, and repair of cells associated 
with activating gene families including, but not limited to: 
BMP, Actin, Thrombospondins, Lamanins, Proteoglycans, 
Collagens, Tumor Necrosis Factors (TNF), Transforming 
Growth Factors TGF, and Cytoskeletal families. 
As used in this paper, a "stimulation field" refers to a 65 
magnetic field generated electromagnetically wherein the 
magnetic field is comprised of a B-Field wherein a particle 
DETAILED DESCRIPTION 
The innovation utilizes stimulation fields of at least one 
predetermined profile to modify the genetic regulation of 
US 8,795,147 B 1 
11 12 
mammalian chondrocytes, osteoblasts, osteocytes, osteo-
clasts, nucleus pulposus, associated tissues, or any combina-
tion. In an embodiment, the at least one predetermined profile 
is tuned in accordance with empirical techniques. Various 
embodiments of the apparatus and method are applicable but 5 
are not limited to the diseases of osteoarthritis and osteoporo-
sis as well as to be used to treat and resolve damaged struc-
tures of the skeletal and soft or connective tissues of the 
physiology. The innovation described herein uses a com-
pletely non-invasive method and protocol to affect the desired io 
results outlined above. The innovation also relates to a 
method of treating diseased tissue in a human through the 
exposure of a tuned or tunable stimulation field of at least one 
tuned predetermined profile to diseased tissue in a human, 
including osteoarthritis, osteoporosis, osteopenia, and other 15 
cartilage/bone diseases, defects, and injuries. 
In an embodiment, the method includes steps associated 
with tuning or selecting a tuned predetermined time-varying 
stimulation field of at least one tuned predetermined profile 
for at least one predetermined time period wherein different 20 
profiles may be employed for different periods of time. It is 
well known that an electrical current flowing through a wire 
generates a magnetic field. The resultant magnetic field is 
produced by the motion of electrical charges, i.e., electrical 
current. However, the specific manner of tuning electrical 25 
signal characteristics or FOMs and to produce a tuned prede-
termined time-varying stimulation field to optimize the re-
growth of tissue based on cellular and sub-cellular observa-
tions is not well-known in the related art. The innovation 
described herein attempts to solve at least some of the prob- 30 
lems described above. 
In an embodiment, the innovation is comprised of a device 
that can be wrapped around a ROI such as, for example, joints 
where damaged cartilage is located. The device may produce 
at least one stimulation field at a pre-determined frequency, 35 
wavelength, magnitude, rise time, rising slew rate, fall time, 
falling slew rate, duty cycle, or any combination that will 
result in tissue modification. For example, this embodiment 
addresses problems associated with invasive surgical tech-
niques by non-invasively applying a TVMF to the affected 40 
areas to regenerate and re-grow cartilage cells, bone cells, or 
both. 
As an example in an embodiment, the inventors have deter-
mined that successful reproducible transmission of electri-
cally generated stimulation fields of predetermined frequency 45 
are comprised of five factors: (1) the profile or waveform of 
the stimulation field comprising predetermined FOMs; (2) a 
sufficient field flux to overcome the ambient environment; (3) 
design of  transmission component (antennae); (4) change of 
slew rate and rise and fall time; and (5) exposure time of the 50 
ROI to the stimulation field. The innovation described herein 
is associated with the inventors' laboratory studies at the 
cellular level designed to elucidate the fundamental underly-
ing mechanisms that link stimulation field exposure to bio-
logical effects. Specifically, the results of the inventors' 55 
research identify mechanisms based on molecular or cellular 
changes that are brought about by stimulation fields of pre-
determined profile thereby providing clues as to how a physi-
cal force is converted or transduced into a biological action 
within a mammalian physiology. 60 
With particular reference to FIG. 7, for example, in an 
embodiment, the innovation comprises a method to modify 
the genetic regulation of mammalian tissue, bone, or any 
combination comprising the steps of: exposing said mamma-
lian chondrocytes, osteoblasts, osteocytes, osteoclasts, 65 
nucleus pulposus, associated tissue, or any combination to at 
least one tuned time-varying stimulation field 11 comprised 
of at least one tuned predetermined profile for a predeter-
mined tuned exposure time or plurality of tuned exposure 
time sequences wherein said at least one tuned predetermined 
profile is comprised of a plurality of tuned predetermined 
figures of merit and is controllable through at least one of said 
plurality of tuned predetermined figures of merit, wherein 
said plurality of predetermined tuned figures of merit is com-
prised of a tuned B-Field magnitude, tuned rising slew rate, 
tuned rise time, tuned falling slew rate, tuned fall time, tuned 
frequency, tuned wavelength, and tuned duty cycle; control-
ling said at least one tuned time-varying stimulation field to 
produce said at least one tuned predetermined profile 12 by 
manipulating said tuned B-Field magnitude, said tuned expo-
sure time or said plurality of tuned exposure time sequences 
and at least one of the following said tuned predetermined 
figures of merit: said tuned rising slew rate, said tuned rise 
time, said tuned falling slew rate, said tuned fall rime, said 
tuned frequency, said tuned wavelength, or said tuned duty 
cycle. The method may be further comprised of the step of 
tuning said at least one predetermined profile 50 associated 
with at least one time-varying stimulation field thereby result-
ing in at least one tuned time-varying stimulation field com-
prised of at least one tuned predetermined profile, wherein 
said at least one tuned predetermined profile is comprised of 
a plurality of tuned predetermined figures of merit and is 
controllable through at least one of said plurality of tuned 
predetermined figures of merit, wherein said plurality of pre-
determined tuned figures of merit is comprised of a tuned 
B-Field magnitude, tuned rising slew rate, tuned rise time, 
tuned falling slew rate, tuned fall time, tuned frequency, tuned 
wavelength, and tuned duty cycle. 
With particular reference to FIG. 8, for example, in an 
embodiment, the step of exposing said mammalian chondro-
cytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus, 
associated tissue, or any combination to at least one tuned 
time-varying stimulation field 11 may be comprised of: pro-
viding a stimulation field generator apparatus in proximate 
spatial relationship to said mammalian chondrocytes, osteo-
blasts, osteocytes, osteoclasts, nucleus pulposus, associated 
tissue, or any combination 18; and generating said tuned 
time-varying stimulation field using said stimulation field 
generator apparatus 19. 
With particular reference to FIG. 9, for example, in an 
embodiment, the step of tuning may be comprised of: provid-
ing at least one set of cellular samples in at least one rotating 
wall vessel 51; exposing said at least one set of cellular 
samples 52 to at least one experimental time-varying stimu-
lation field comprising at least one experimental predeter-
mined profile; conducting at least one gene expression analy-
ses to said at least one set of cellular samples 53; analyzing the 
genetic anabolic and catabolic effects from the results of said 
at least one gene expression analyses 54; generating at least 
one conclusion from said step of analyzing 55; adjusting said 
at least one experimental predetermined profile based on said 
at least one conclusion 56; and selecting at least one tuned 
time-varying stimulation field comprised of at least one tuned 
predetermined profile for a predetermined tuned exposure 
time or a plurality of tuned exposure time sequences 57. In an 
embodiment, the step of conducting at least one gene expres-
sion 53 may occur after said step of exposing said at least one 
set of cellular samples 52. In an embodiment, the step of 
adjusting said at least one experimental predetermined profile 
56 may occur if said at least one conclusion does not meet 
predetermined criteria. The at least one set of cellular samples 
may be selected from the group consisting of human chon-
drocytes and human osteoblasts in addition to associated 
tissues. 
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With particular reference to FIG. 10, for example, in an 	 genes responsible for the restoration, repair, maintenance, or 
embodiment, the step of analyzing the genetic anabolic and 	 any combination of cartilage and bone. 
catabolic effects 54 may be comprised of: selecting a prede- 	 With continued reference to FIG. 3, the power source 31 
termined set of genes or gene families 58; calculating a fold 	 supplies an electrical current to the control component 32 
change for each gene in said set of genes from the results of 5 wherein the supplied electricity flows through the transmis- 
said at least one gene expression 59; determining if each of 	 sion component 33 thereby emitting a magnetic field 34. 
said fold change is consistent with up-regulation or down- 	 Multiple embodiments of a power source exist. For example, 
regulation for said each gene 60; and classifying each of said 	 the power source 31 may comprise a battery; a power con- 
fold change as an anabolic or catabolic effect based on said 	 verter that converts one form of electrical power to another 
up-regulation or down-regulation for said each gene 61. 	 io desired form and voltage (e.g., a device that converts 120 or 
With particular reference to FIG. 11, for example, in an 	 240 voltAC supplied by a utility company to a well-regulated 
embodiment, the said step of generating at least one conclu- 	 lower voltage DC for electronic devices; low voltage, low 
sion 55 may be comprised of: establishing a relative value for 	 power DC power supply units are commonly integrated with 
each of said anabolic or catabolic effect on said up-regulation 	 the devices they supply, such as computers and household 
or down-regulation for said each gene 62; comparing each of 15 electronics); a switched-mode power supply; a linear regula- 
said relative value in combination 63; selecting a conclusion 	 tor, a rectifier; a high capacity capacitance power source; an 
comprised of either a substantive net anabolic effect, a sub- 	 electrical outlet power source; or any combination. 
stantive net catabolic effect, a net anabolic effect, a net cata- 	 With continued reference to FIG. 3, the control component 
bolic effect, or no determinative effect 64. 	 32 of the apparatus 30 is used to produce a desired electrical 
In an embodiment, a substantially square wave signal with 20 signal, thereby in combination with the power source 31 and 
a frequency from about 10 Hz to about 200 Hz can be induced 	 transmission component 33, produces a stimulation field of 
to a ROI via a transmission component with the intent of 	 predetermined profile 10. The resultant stimulation field is 
influencing and thereby modifying the sub-cellular molecular 	 further induced to a target tissue or ROI 21 by the transmis- 
components of mammalian chondrocytes, osteoblasts, osteo- 	 sion component 33, which will be discussed later. Multiple 
cytes, osteoclasts, nucleus pulposus, (and associated tissue) 25 embodiments of a control component 32 exist. For example, 
thereby affecting the genomic and proteomic output or 	 the control component 32 may comprise a voltage or amper- 
expression of these cells. The expression deltas are directly 	 age driven signal generator as known as a function generator, 
responsible, as compared to controls (untreated cells), for 	 arbitrary waveform generator, digital pattern generator, pulse 
signaling differences at the sub-cellular and nuclear levels of 	 generator, or frequency generator; computerized dongle cir- 
the cells. The inventors have determined through laboratory 30 cuitry with integrated firmware and software; a conductor; an 
tests that various embodiments of a stimulation field with a 	 amplifier; a sensor; a microprocessor; or any combination. 
predetermined profile via manipulation of an electrical sig- 	 With continued reference to FIG. 3, the transmission com- 
nal's FOMs, with specific ranges of electrical signal charac- 	 ponent 33 delivers the stimulation field of predetermined 
teristics used to generate a stimulation field of predetermined 	 profile to the target area in the proper field density. Multiple 
profile, result in modification of cartilage and bone cells. For 35 embodiments of a transmission component 33 are available. 
example, a time-varying stimulation field of predetermined 
	
For example, in an embodiment, the transmission component 
profile comprised of a particular B-Field magnitude, fre- 	 33 comprises a wire, wherein the wire is wound into a coil 
quency, rise time, fall time, slew rate, and wavelength for a 	 about a core, wherein the turns of the wire sit substantially 
predetermined exposure time or plurality of exposure time 	 side-by-side. When an electrical current is run through the 
sequences (i.e., an exposure time schedule) may be used to 40 wire, an electrically generated magnetic field or electromag- 
preferentially excite specific sub-cellular organelles within 	 netic field passes through the center of the coil. An alternating 
the subject cells resulting in the desired events previously 	 current may be employed to thereby generate an electromag- 
enumerated. The resultant profile may be a substantially 	 netic field profile that alternates with respect to direction. 
square waveform. 	 Multiple embodiments exist in regard to the shape and design 
Laboratory tests (discussed in more detail later) were com-  45 of the coil. For example, the coil may form the shape of a 
prised of exposing separate ROIs to a time-varying stimula- 	 straight tube; a helix (similar to a corkscrew) such as a sole- 
tion field of predetermined profile and a PEMF of predeter- 	 noid; a solenoid that is bent into a donut shape (i.e., a toroid); 
mined profile wherein the ROIs was comprised of a rotating 	 or any combination. The transmission component may also 
wall vessel (RWV). The RWV was inserted into a transmis- 	 comprise a container of a predetermined shape and size 
sion component (see FIG. 5). The RWV contained a prede-  50 wherein the wire is radially disposed on the container thereby 
termined volume of microcarriers and predetermined cell 
	
forming the coil. Still further, in an embodiment, the trans- 
volume comprised of human chondrocytes or human osteo- 	 mission component may also comprise a sleeve 20 capable of 
blasts; and cell growth media. Both 2D and 3D culturing 	 wrapping around an appendage associated with a mammalian 
techniques were employed. Cell growth observations and 	 physiology wherein the ROI 21 is associated with said mam- 
analysis were then performed. 	 55 malian physiology. 
Stimulation Field Generator Apparatus 	 Resultant Time-Varying B-Field 
With particular reference to FIG. 3, in regard to the stimu- 	 In an embodiment, the stimulation field generator appara- 
lation field generator apparatus 30 mentioned above, an appa- 	 tus 30 is tuned to deliver a stimulation field of predetermined 
ratus 30 is provided to electrically generate a stimulation field 	 profile 10 to preferentially stimulate the biochemical cellular 
of predetermined profile 10. The apparatus 30 may include 6o and sub-cellular molecular responses to trigger the activation 
several components including: 1) a power source 31, 2) a 	 of known mammalian genes responsible for the restoration, 
control component 32, and 3) a transmission component 33. 	 repair, modification, and maintenance of cartilage and bone. 
The apparatus 30 is effectively tuned via an electrical signal 
	
Production of the desired profile is accomplished by control- 
of predetermined profile to subsequently deliver  stimulation 	 ling the electricity transferred within the stimulation field 
field of predetermined profile 10 to preferentially stimulate 65 generator apparatus 30. As discussed previously, the electric- 
the biochemical cellular and sub-cellular molecular 	 ity or electrical flow is controlled by the control component 
responses to trigger the activation of known mammalian 	 32. The control component 32 manages the electricity in 
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terms of an electrical signal. An electrical signal may be 	 expands. The result of this effort was an additional 4.5x108 
representative of a voltage, current, or both and conveys time- 	 cells per sex or 9x108 total cells. 
based information. Further, in an embodiment, additional 
	
Human Osteoblasts 
management of the electrical signal may be conducted to 	 In laboratory testing, human osteoblasts (HOBS) were 
normalize the total energy; to selectively modulate the result-  5 cryopreserved. Again, the HOBS were received from older 
ant profile or waveform; to normalize the profile's duty cycle, 	 donors, in this case ranging in age from 50 to 59 and from both 
rising slew rate, falling slew rate, etc.; or any combination. 	 male and female donors. Like the HCH, each lot/donor was 
With particular reference to FIG. 1, in an embodiment, a 	 expanded and banked as an individual, and then combined by 
resultant simulation field of predetermined profile 10 is com- 	 sex into multi-donor pools, yielding a pool of five male 
prised of a substantially biphasic, square waveform. In an io donors and an additional pool of five female donors. 
embodiment, a substantially biphasic, square waveform com- 	 Cell Growth Media 
prising a frequency in the range from about 9 Hz to about 200 
	
Cell growth media, GTSF-2, was originally formulated at 
Hz may be employed. Further, a resultant profile with the 	 the National Aeronautics and Space Administration/Johnson 
following FOMs may be employed: a B-Field magnitude 	 Space Center by Dr. Goodwin with a U.S. patent issuing in 
from about 0.6 G to about 200 G; a rise time from about 125 15 1998. (Goodwin, 1998) GTSF-2 is a tri-sugar, double-buff- 
µs to about 1 ms; a rising slew rate from about 2.0 kG/s to 	 ered media custom formulated on an L-15/Alpha-MEM base. 
about 50.0 kG/s; a fall time from about 125 µs to about 1 ms; 	 Cells grown in two dimensions (2D) in standard flasks or 
• falling slew rate from about 5.0 kG/s to about 50.0 kG/s; and 	 plates are exposed to such an unnatural condition that their 
• duty cycle of between 65-80% (and a subsequent dwell time 	 growth requirements are skewed as compared to in vivo. 
of between 20-35%). Additional FOMs may be employed 20 Hence, just about any glucose-containing, single-buffered 
such as wavelength, exposure duration, etc. FIG.1 illustrates 	 isotonic salt solution will sustain them with minor exceptions 
a time-varying stimulation field profile for a stimulatory 	 as to primary, transformed, transfected or immortalized cell 
waveform for use in bone and tissue healing according to an 	 status. The RWV however creates a more in-vivo like envi- 
embodiment of the present innovation. 	 ronment. Cells are largely free from the pull of gravity and 
Rotating Wall Vessels 	 25 fluid shear, and are able to fully express their natural DNA 
As described above and with particular reference to FIG. 4, 	 encoded characteristics. That is, they are able to differentiate 
RWVs 40 were used in laboratory experiments. Said RWVs 	 and develop cellular structures similar to or even exactly like 
are comprised of a base unit 41, a controller unit 42, and a 	 their in-vivo counterparts. With a more complete growth 
culture vessel (aka vessel) 43. The RWV base unit 41 makes 	 capability, the need for a more complete media arises. 
up the mechanical portion of the RWV 40. Briefly, the base 30 GTSF-2 provides this complete media utilizing glucose, 
unit contains a small air pump to provide circulation along the 	 galactose and fructose as simple and increasingly complex 
spin filter in the center of the culture vessel, and a stepper 	 energy sources, as well as HEPES and NaHCO3 (sodium 
motor designed to spin the weight of all culture vessels. The 	 bicarbonate) to ensure pH remains as close to physiologic 
RWV controller unit 42 houses electronics specifically cre- 	 normal as possible even in the most growth-active cultures. 
ated to energize the stepper motor within the base unit 41 to a 35 GTSF-2 is now available in several commercial formulations 
consistent and calibrated rate, providing for equal rotation 	 via their "specialty media" group as DPMI 40% MEM 
speeds between set ups so that each unit in service can be spun 	 ALPHA MOD/60% L-15, catalog number SH3A099.0L 
at identical rates. The RWV culture vessel 43 may be com- 	 Two-Dimensional (2D) Culturing Techniques 
prised of a Slow Turning Lateral Vessel (STLV) or a High 	 In order to preserve as many vials of low passage cells as 
Aspect Rotating Vessel (HARV). Cell samples 44 are con-  40 possible and extendthe life ofthe cryo-pool of cells to accom- 
tained in the culture vessel 43. Cell samples 44 may comprise 	 modate any future needs, a single vial of frozen HCH or HOB 
chondrocytes, nucleus pulposus, osteoblasts, osteoclasts, 	 pooled cells is thawed to initiate cells for bioreactor experi- 
osteocytes, associated tissue, or any combination. Each STLV 	 ments. From a single 1x107 cells/vial unit, we are able to 
is comprised of a base, a barrel, a center core for oxygenation, 	 expand into as many as 2x108 cells, enough cells to populate 
a cap with syringe ports, and a fill plug. To offset the potential 45 twelve STLVs, without passage beyond p7. Standard cultur- 
damage to cells from off-gassing, new HARVs and STLVs 	 ing techniques are used. T-flasks purchased from Corning and 
must be rigorously detoxified in a procedure involving etha- 	 GTSF-2 media with 10% FBS are used to expand the HOB or 
nol and autoclaving before first use. 	 HCH cells sufficiently to meet the required numbers for the 
Human Chondrocytes 	 designed experiment. As the cell population within the flask 
In the laboratory tests, the HCH's were comprised of 5o reaches a cell density of approximately 75-80%, cells are 
articular chondrocytes from donors ranging in age from 	 passaged into a new flask using standard trypsinization tech- 
50-85, and both male and female donors. These are primary 	 niques at a density roughly 25% of the previous flask. In other 
cell populations not established or immortalized cultures. 	 words, one flask is passaged into four. This continues until 
Seven male lines and seven female lines were studied. Each 	 enough flasks are available to yield the necessary number of 
individual donor was cultured in 2D and expanded until a 55 cells. It should be noted that continued growth of primary 
minimum of 5x10' cells could be cryopreserved. Following 	 cells is difficult and time consuming as normal cells are not 
initial, individual expansion, one vial of each donor was com- 	 known to be sustained in 2D culture for prolonged periods. 
bined into a pool, keeping male donors separate from female 	 Microcarrier Preparation 
donors, and expanded in 2D until an additional 1 x10 $ cells in 	 Several different microcarrier substrates are available in a 
pool could be cryobanked. This combined pool never 60 variety of configurations to suit the need of the tissue being 
exceeded passage 7. One should not lose the primary charac- 	 recapitulated. For example, PGA (polyglycolic acid), cyclo- 
teristics of the cells in culture and therefore effort was 	 dextran, collagen and gelatin are exemplary forms of micro- 
expended into maximizing the number of cells available 	 carrier substrates. In an embodiment, gelatin microcarriers, 
while minimizing the number of ex-vivo passages. Addition- 	 commercially and readily available from Sigma-Aldrich (St. 
ally, by banking as individuals first, then creating a pool, this 65 Louis, Mo.), called Cultispher were employed. Cultispher is 
technique provides the capability to "go back" and create 	 a macroporous gelatin bead, coated with gelatin. Since the 
additional vials of pooled cells if experimentation focus 	 primary HCH and HOB are expensive and available in limited 
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quantity, the increased surface area allows for better cell 
density with a lighter cell load. Cultispher is also fairly simple 
to use. It's provided as a dry powder and weighed out in 
milligrams based on the culture. Roughly 3 mg/ml into a 55 
ml STLV is sufficient growth space for NCH and HOB cul- 5 
tures. Once the desired amount is weighed, the microcarriers 
are placed into a small, autoclavable jar and phosphate buff-
ered saline (PBS) is added in sufficient quantity so that they 
can rehydrate properly. The microcarriers are allowed to 
"soap' in PBS overnight. The following day the microcarriers io 
are autoclaved to ensure sterility. After autoclaving, they must 
be refrigerated overnight before use. 
Initiation of Three-Dimensional (3D) Cultures 
The quantity of cells and microcarriers used in any of the 
culture vessels is dependent on a number of factors. For the 15 
laboratory tests, the HCH and HOB are primary cells. As such 
they require a starting cell density considerably higher than 
that of a transformed or transfected cell lines. Additionally, in 
order for the RWV to work properly, cell density in relation to 
spatial and fluid limitations must be considered. The balance 20 
is adding enough cells for the crucial, initial cell-cell interac-
tions that will establish the culture but not adding so many 
such that towards the end of the culture period the cell density 
is too great to be supported in the fluid volume and head space 
of the vessel. After a few limited trials, it was determined that 25 
an initial seeding density of 3) (1.05 cells/ml/vessel was a 
good balance for HCH and HOB cells. Using standard 
trypsinization techniques, the HCH or HOB cells were 
removed from the 2D flasks used to expand the HCH or HOB. 
The HCH or HOB cells were stored in media while perform - 30 
ing cell counts. In an embodiment, hemacytometers and try-
pan exclusion techniques were used to determine cell counts. 
Once the number of cells per mL is determined, a predeter-
mined amount of the cells were loaded into the vessel to equal 
the desired concentration. Next, pre-measured, pre-sterilized 35 
microcarriers were added. Finally, the remaining volume 
with GTSF2 media was added. After all culture components 
are loaded, air and all subsequent air bubbles were removed, 
and the vessel pressurized. This is accomplished via the 
syringe ports on the top of the vessel. By filling a syringe with 40 
media and repetitively squirting that media into the vessel 
while pulling air out, all dead/air space in the vessel can be 
filled. After all the bubbles have been removed in this manner, 
putting pressure on the fluid in the syringe creates pressure 
within the vessel. The vessels were subsequently pressurized 45 
and capped off. The vessel is now ready to be mounted on the 
base unit of the RWV. 
3D Culture Maintenance 
Generally speaking, the cultures are not fed within the first 
48 hours after initiation. This allows the cells time to bind 50 
with the microcarriers and begin to produce the proteins 
responsible for cell-cell communication and adhesion. Feed-
ings thereafter are determined via I-STAT® (Abbott Labs, 
Princeton, N.7.), a hand-held portable blood gas analyzer 
whichis usedinhospitals andclinics worldwide. The analysis 55 
it performs is dependent on the cartridge used. For culturing 
purposes, Na+ and Cl+ ions present in the supernatants are an 
indicator of cell metabolism in that NaCl is cleaved during 
uptake. Glucose is also notable. Glucose is one of three sugars 
in GTSF-2 and the only one that can currently be analyzed 60 
consistently. It is a primary energy source for the cells and the 
quantity used in any period of time between feedings provides 
information on the activity level of the cells. BUN (blood urea 
nitrogen) readings on the I-STAT® correlate with stress levels 
within the culture. NaHCO 3 (sodium bicarbonate) levels pro- 65 
vide information about the quantity of acid produced as a 
result of metabolic activity. These various ions plus other 
parameters the I-STAT® measures, are essential to making 
good decisions as to quantity and frequency of feeding of the 
cultures. The ultimate goal is to maintain as physiologic nor-
mal within the bioreactor. A pH of 7.2, roughly 80-100 mg/dL 
of glucose, and adequate but not excessive salt and bicarbon-
ate to balance the solution are achieved to maintain proper 
isotonicity. Deviations measured each 24 hour period from 
normal and the time it takes for them to occur is how the 
maintenance schedule for the cultures are determined. 
Analytical Techniques Utilized Post-Experiment 
Light microscopy is also used in conjunction with immu-
nohistochemistry (IHC). Cells are embedded in a paraffin 
matrix, then thin layers are cut and mounted on slides. These 
slices are then stained with an antibody conjugated to a color 
of some kind or to a flourochrome to make the binding site 
visible. The antibodies can be to a cell type specific antigen 
found only in that specific cell. The antibodies can also be to 
a protein or cytokine product being produced by the cell. The 
slides with the tissue slices mounted on them are then viewed 
via a microscope—either light or confocal and photo-
graphed for analysis and publication. Concentration of the 
color or flourochrome on the cell is indicative of the quantity 
of the antigen or protein in question. Dark coloring means 
high binding and high presence whereas light coloring is a 
reduced presence and low binding. IHC is generally consid-
ered a "qualitative" assessment however and other techniques 
are used to "quantify" marker expression. A portion of tissue 
like assemblies are aliquoted, washed 3x with filter-sterilized 
water, aspirated, and fixed in a final concentration of 2% 
Glutaraldehyde/3% Formaldehyde prepared in PBS. The 
samples are fixed for a minimum of 24 hrs at 4° C. overnight. 
The samples are flushed in triplicate with filter-sterilized 
deionized water to remove salts and then transferred for 
observation and imaging to a FEI XL30 Environmental Scan-
ning Electron Microscope. Genetic array analyses are per-
formed on experiments after eachmajor change inparameters 
or change in cell type. 
Laboratory Testing 
The inventors have conducted several experimental studies 
on the effects of time-varying stimulation fields on cellular 
processes. For example, in a study, a mixed population of 
human chondrocytes (HCH) was created and banked from 
patient samples ranging in age from 58 through 81 years. 
These samples were specifically selected due to their indica-
tions of early stage osteoarthritis. A male test population was 
exposed to a stimulation field of predetermined profiles com-
prising a predetermined B-Field magnitude and waveform 
shape, produced by an electrical signal in a continuous man-
ner for about 30 days in a RWV. FIG. 5 illustrates an exem-
plary set-up incorporating the integration of a RWV and a 
stimulation field generator. Cellular gene expression analyses 
comprised of fold change analyses were accomplished by an 
AFFYMERIX® Gene Array survey of 47,000 human genes 
(U133 Plus 2.0 Chip) using the HCH samples exposed to the 
stimulation field as well as control HCH samples. The expres-
sion results were confirmed by a Reverse Transcriptase Poly-
merized Chain Reaction (RT-PCR) or LUMINEX® Assays. 
The inventors observed a difference between the types of 
regulated genes (discussed later). The inventors repeated the 
experiment, however, this time, two sets of HCH samples 
were each exposed to separate stimulation fields of predeter-
mined profile (one stimulation field for each set of samples). 
The B-Field magnitude for each stimulation field was differ-
ent in this experiment. After a similar gene array survey 
(described above), the inventors again observed a difference 
between the types of regulated genes exposed to the different 
stimulation fields. The inventors again repeated the experi- 
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ment, however, this time; two HOB samples were exposed to 	 approximately 47,000 human genes exposed to multiple 
separate stimulation fields of predetermined profile (one 	 stimulation field profiles as regulated by multiple electrical 
stimulation field for each set of samples). The B-Field mag- 	 signals was conducted. 
nitude for each stimulation field was substantially equal in 	 Similar experiments were performed with human osteo- 
this experiment. Due to a consensus in the related art, it was 5 blasts. In addition, the same result in regard to stimulation 
anticipated that any cellular activity, expressed in cellular 	 fields of different profiles inducing regenerative (e.g., ana- 
gene expression analysis, would be relatively equal because 	 bolic) vs. reparative (e.g., catabolic) genes was observed but 
the related art suggests that a B-Field's magnitude is the 	 with increased genetic activity. A sample set of experimental 
determinative variable. However, the experiment yielded 	 results is as follows wherein said sample set are provided for 
unanticipated results. Specifically, a subsequent gene array io the purpose of illustrating the development of the innovation 
survey revealed significant differences in gene expressions 	 as well as various embodiments of the innovation and are not 
between the two cell samples. Also, the inventors observed 	 meant to limit the present innovation in any fashion. 
for the third time differences in the type of regulated genes 
exposed to the different stimulation fields. As an example, the 	 Example 1 
gene array survey results from these experiments indicate 15 
significant differences between stimulation field profiles in 	 Human Chondrocytes 
regard to potential use for osteoarthritis treatment. The results 
clearly indicate preferential regulation of cellular mecha- 	 In a first experiment, a first set of HCH cell samples con- 
nisms identified with human chondrogenesis, osteogenesis, 	 tained in at least 3 RWVs were exposed to a first time-varying 
and extracellular matrix (ECM) deposition from a set of spe- 20 stimulation field of predetermined profile comprised of sub- 
cific signals wherein B-Field magnitude is not the determi- 	 stantially a biphasic, square wave with a frequency of about 
native variable. Rather, the shape of a stimulation field profile 	 10 Hz; a wavelength of about 500 ms; a rising slew rate 
(i.e., waveform) and FOMs (in addition to a B-Field magni- 	 between about 0.2 T/s (2.0 kG/s) to about 0.45 T/s (4.5 kG/s); 
tude) are also influential factors. 	 a falling slew rate between about 0.45 T/s (4.5 kG/s) to about 
In an embodiment, preparation of human chondrocytes 25 1.5 T/s (15.5 kG/s); a dwell time of about 10% after each 
was performed as follows: the mixed population of human 	 burst; a duty cycle of about 80% on and about 20% off; and a 
chondrocytes described above was expanded in culture flasks. 	 resultant B-Field magnitude of about 5.9 µT (0.059 G). The 
First, tissue-like-assemblies (TLAs) were constructed from 	 experiment was conducted at 10 Hz. For reference purposes, 
normal human chondrocytes. From these TLAs, cell samples 	 the frequency of Earth's geomagnetic field is 7.83 Hz, thus 
were grown (i.e., expanded) in two-dimensional (2D) culture 30 the experiment satisfies the criteria of being appreciably dif- 
flasks. The cell sample population was derived from several 
	
ferent from the background magnetic field. Exposure was 
patient samples wherein these samples were pooled and gen- 	 continuous for the length of this experiment wherein said 
der isolated. The subsequent cultures were established in a 	 length was about 30 days or about 720 hours. Gene analysis 
GTSF-2 growth medium. GTSF-2 growth medium is a basal 	 comprising a fold change analysis as describe above was 
cell culture medium. In addition to traditional growth-factors, 35 conducted for the HCH cell samples exposed to the first 
GTSF-2 contains a blend of three sugars (glucose, galactose, 	 time-varying stimulation field. Exemplary results from said 
and fructose) at their physiological levels. The cultures were 	 gene analysis associated with the first time-varying stimula- 
removed from the 2D flasks by trypsin-EDTA and counted. 	 tion field are provided in Table 2 below. 
Exposures of these chondrocyte cell samples to a predeter- 	 Generally, the related art consensus teaches that a field 
mined time schedule of stimulation fields of predetermined 40 strength (either electric or magnetic) should be sufficiently 
profiles were performed in the following manner. A known 	 powerful enough to penetrate deep enough inside cells to 
cell volume was inoculated into at least three rotating wall 	 cause the desired effect. In order for this to happen the applied 
vessels (RWVs) for each sample set and a control sample set 	 energy levels must be sufficiently high to penetrate deep 
wherein the RWVs are associated with a rotating bioreactor, 	 enough inside cells, otherwise only a minimal and superficial 
such as a RCCS-1 system, which is a commercial unit manu- 45 effect can be expected. Electric fields are more susceptible to 
factured by Synthecon, Inc. RWVs were inserted into a pre- 	 shielding effects as compared to magnetic fields. As 
determined coil designed to deliver a stimulation field of 
	
described above, the laboratory set-up comprised the use of at 
predetermined profile comprised of a predetermined set of 
	
least 3 RWVs for the first set of HCH samples wherein the at 
FOMs. The RWVs contained a predetermined volume of 
	
least 3 RWVs were each enclosed within wire coils designed 
microcarriers. Electricity was subsequently supplied to the 50 to generate a magnetic field. Thus, the level of interference 
coil in accordance with a predetermined profile. In the simu- 	 was minimized and the relatively low B-Field magnitude of 
lated microgravity environment of the RW V, the human chon- 	 the first time-varying stimulation field did result in the regu- 
drocyte (HCH) and human osteoblasts (HOB) cells adhered 	 lation of over 2000 genes. However, consideration as to 
to new growth matrices and began to multiply in cell-bead 	 applying an equivalent "effective" B-Field magnitude to a 
aggregates. The cell-bead aggregates were allowed to develop 55 mammalian subject may require increasing the B-Field mag- 
for a predetermined exposure time or plurality of exposure 	 nitude by a predetermined amplification factor of predeter- 
time sequences wherein multiple embodiments exist thereto 	 mined value or "gain" thereby requiring the creation of a dose 
(e.g., for about 30 days; between about 1 hour and about 720 	 response curve. This amplification factor or gain may be 
hours; for 24 hours on, 24 hours off, repeat for a total of 30 	 required due to differences in the level of interference asso- 
days; etc.). 	 60 ciated with the inventors' laboratory set-up and a mammalian 
Cell growth observations and analyses were then per- 	 physiology (e.g., skeletal structure comprised of bone). The 
formed using the sample set(s) which were contained in at 	 inventors stipulate that translation of the "optimum" effective 
least 3 RWVs per sample set and a control sample set also 	 field and conditions must take into account the systemic 
comprised of samples contained in at least 3 RWVs. Gene 	 dampening encountered by the application to an entire physi- 
analyses were accomplished by anAFFYMETRIX® GENE- 65 ology. 
CHIP® Human Genome U133 Plus 2.0 Array, RT-PCR, or 	 It is noted that an unanticipated observation was made in 
LUMINEX® Assay. A survey of the entire human genome of 	 regard to the type of genes that were regulated. Specifically, 
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the inventors discovered that genes normally associated with TABLE 2-continued 
a regenerative function (i.e., anabolic genes) were up-regu- 
lated at a much higher percentage as compared to genes Fold 	 Anabolic or Catabolic 
reparative function i.e., catabolic ( p 	 genes). associated with a  	 In 
 
Increase/Decrease 	 Effect 
for First 	 of Genes Associated 
some cases, genes exposed to the first time-varying stimula- 5 Time-Varying 	 with Chondrocyte 
tion field were down-regulated thereby resulting in a cata- Gene Family Stimulation Field 	 Development 
bolic effect or up-regulated thereby resulting in an anabolic Latent Transforming Growth 
effect, or vice-versa. In an embodiment, a set of genes may be  Factor (TGF) Family (ECM) 
selected based on known function(s). The fold change for 
each 	 is said set may be analyzed and determined to be gene 10 Latent TGF Beta Binding +6s4 	 Anabolic g 	 Y 	 Y Protein 2 
consistent with up-regulation, down-regulation, or no regu- Latent TGF Beta Binding +3.71 	 Anabolic 
lation. Eachregulated gene may be subsequently analyzed for Protein 3 
an anabolic effect, catabolic effect, or no differential reula- Integr in Family (Cell sulfur- B 	 d ase g Based [Sur]: ECM) 
tion (NOR). In a further embodiment, a relative value for each 15 
anabolic and catabolic effect may be assigned. And, the entire Integrin beta-like 1 +6.45 	 Anabolic 
set of anabolic and catabolic effects may be compared in with 
 
growth factor or (EGF) hke l 
terms of the relative values of each effect. Thus, the resultant repeat domains 
anabolic vs. catabolic effects may be determined. It should be Inogrin beta 2 (ITGB2) +4.38 	 Anabolic 
noted that many of the genes (anabolic) up-regulated in this 20 complement component 
experiment are associated with embryonic development 
3, receptor 3, and 4 
subunit 
(Lanza, 2000). Table 1 provides a summary of said effects for Inogrin beta 3 binding +2.93 	 Anabolic 
the first experiment. protein (beta3-endonexin) (ITGB3BP) 
Interleukin (IL) Family 
TABLE 1 25 	 (Cellular Cytokine Response) 
# Genes 	 # of Anabolic 	 # of Catabolic IL-32 +3.92 	 Anabolic 
Stimulation Field 	 Regulated 	 Gene Effectst 	 Gene Effectst IL-33 (IL-1 super family) +3.39 	 Anabolic 
IL-1 receptor (IL-1R1) (IL-1 +2.95 	 Anabolic 
First Time- 	 2021 	 37 	 11 super family) 
30 	 IL-4 inducible 1 (IL-4I1) +3.01 	 Anabolic  Varying (TH2 induction)  
Stimulation Field IL-8 -4.82 	 Anabolic 
IL-6 -2.66 	 Anabolic 
tln exemplary results in accordance to Table 1. IL-24 -3.41 	 Catabolic 
IL-17A -2.87 	 Anabolic 
As can be observed in Table 1, the exemplary results for the 35 	 Thrombospondin Family 
first time-varying stimulation field are indicative of anabolic (COMPS)  
or regenerative effects. Table 2 provides additional details Thrombospondin 2 +4.79 	 Anabolic 
with respect to this observation wherein anabolic and cata- (THBS2) 
bolic effects are identified. Thrombospondin 3 +3.73 	 Anabolic (THBS3) 
40 Laminin Family 
TABLE 2 
Laminin Beta 1 (LAMBI) +3.14 	 Anabolic 
Fold 	 Anabolic or Catabolic Laminin Beta 2 (LAM132) +2.91 	 Anabolic 
Increase/Decrease 	 Effect Laminin Gamma 1 +2.82 	 Anabolic 
for First 	 of Genes Associated (LAMCI) 
Time-varying 	 with Chondrocyte 45 	 Proteoglycan Family 
Gene Family 	 Stimulation Field 	 Development 
Biglycan (BGN) +6.45 	 Anabolic 
WNT Family Aggrecan (ACAN) +3.81 	 Anabolic 
PAPLN (Papilin) +3.38 	 Anabolic 
WNT513 	 +3.43 	 Anabolic Chondroitin Sulphate +3.16 	 Anabolic 
WSPI 	 +3.41 	 Anabolic 50 Proteoglycan 4 (CSPG4) 
WSP2 	 +3.03 	 Anabolic Hyalmonan and +4.66 	 Anabolic 
Bone Morphogenetic Proteoglycan Link protein 
Protein (BMP) Family 1 (HAPLN 1) 
Proteoglycan 4 (PRG4) +2.85 	 Anabolic 
BMP2 	 -8.63 	 Catabolic Collagen Family 
BMP6 	 -4.56 	 Catabolic 55 
Forkhead Box (FOX) Family Collagen, Type 1, Alpha 1 +32.67 	 Anabolic 
(COL1A1) 
FOXFI 	 -3.32 	 Catabolic Collagen, Type 3, Alpha 1 +4.23 	 Anabolic 
FOXN3 	 -4.00 	 Catabolic (COL3A1) 
Sex Determining Region  Collagen, Type 4, Alpha 4 +3.53 	 Anabolic 
(SRY) SOX Family (COL4A4) 60 	
Collagen, Type 5, Alpha 1 +7.52 	 Anabolic 
SOX9 (SRY-box 9) 	 -3.03 	 Catabolic (COL5A1) 
SOX10 (SRY-box 10) 	 -2.91 	 Catabolic Collagen, Type 5, Alpha 2 +6.54 	 Anabolic 
Parathyroid Hormone (PTH) (COL5A2) 
Family Collagen, Type 6, Alpha 2 +4.00 	 Anabolic 
(COL6A2) 
PTHLH (PTH-like hormone 	 -11.00 	 Catabolic 65 	 Collagen, Type 8, Alpha 2 +3.63 	 Anabolic 
[LH]) (COL8A2) 
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TABLE 2-continued 
Fold Anabolic or Catabolic 
Increase/Decrease Effect 
for First of Genes Associated 
Time-Varying with Chondrocyte 
Gene Family 	 Stimulation Field Development 
Collagen, Type 12, Alpha 1 +3.93 Anabolic 
(CGL12A1) 
Collagen, Type 16, Alpha 1 +3.68 Anabolic 
(CGL16A1) 
Collagen, Type 21, Alpha 1 +5.54 Anabolic 
(CGL21A1) 
Collagen, Type 27, Alpha 1 +5.06 Anabolic 
(CGL27A1) 
Insulin (INS) Family 
Insulin-Like Growth Factor —13.18 Catabolic 
(IGF) Binding Protein (BP) 
1 
IGFBPS —5.03 Catabolic 
INS —2.89 Catabolic 
As can be observed in Table 2, several select genes of 
interest experienced up or down-regulation in the first experi-
ment. For example, BMPs are a group of growth factors also 
known as cytokines originally discovered for their ability to 
induce the formation of bone and cartilage and are also con-
sidered to constitute a group of pivotal morphogenetic sig-
nals, orchestrating tissue architecture throughout the body. 
With specific reference to BMP2, BMP2 was down-regulated 
in the first experiment. BMP2 acts as a disulfide-linked 
homodimer and induces bone and cartilage formation and 
plays a key role in osteoblast differentiation. Further, BMP2 
has been shown in clinical studies to be beneficial in the 
treatment of a variety of bone-related conditions including 
delayed union and non-union and has received FDA approval 
for clinical uses and is considered a repair or catabolic gene. 
In this experiment, the down-regulation of BMP2 represents 
a catabolic effect. Particularly as the goal was to enhance the 
growth of human chondrocytes. Also as will be seen in an 
experiment discussed later, a very similar application of a set 
of FOMs will result in the up-regulation of BMPs. Thus, this 
experiment demonstrated that changes in FOMs as well as 
overall B-Field can significantly change outcomes. As 
another example, collagen is a protein that strengthens and 
supports many tissues in the body, including cartilage, bone, 
tendon, and skin. Genes have been discovered that encode 
components of collagen. When these genes are up-regulated, 
an anabolic effect occurs. Conversely, when these genes are 
down-regulated, a catabolic effect occurs. In this experiment, 
the up-regulation of the genes in the collagen family repre-
sents an anabolic effect. It is noted that in some instances, the 
effects of up-regulation, down-regulation, or a combination 
of both of a gene; a combination of specific genes; a family of 
genes; a plurality of gene families can be substantive; or any 
combination can be substantive. 
Example 2 
Human Chondrocytes 
In a second experiment, a second set of HCH cell samples 
contained in at least 3 RWVs were exposed to a second 
time-varying stimulation field of predetermined profile com-
prised of substantially a biphasic, square wave with a fre-
quency of about 10 Hz; a wavelength of about 500 ms; a rising 
slew rate between about 0.2 T/s (2.0 kG/s) to about 0.45 T/s 
(4.5 kG/s); a falling slew rate between about 0.45 T/s (4.5 
kG/s) to about 1.55 T/s (15.5 kG/s); a dwell time of about 10% 
24 
after each burst; a duty cycle of about 80% on and about 20% 
off, and a resultant B-Field magnitude of about 65 µT (0.65 
G). A third set of HCH cell samples contained in at least 3 
RWVs were also separately exposed to a third time-varying 
5 stimulation field of predetermined profile comprised of a 
substantially monophasic, delta wave with a frequency of 
about 15 Hz; a duty cycle of about 30% on and about 70% off, 
and a resultant B-Field magnitude of about 250 µT (2.5 G). 
The third time-varying stimulation field is generally illus- 
lo trated in FIG. 2. Note that the waveform represented in the 
third time-varying stimulation field may be designated a 
"pulse" or "burst" due to both its shape and wavelength (aka 
a "pulsed time-varying stimulation field"). Exposures were 
15 continuous for the length of this experiment wherein said 
length was about 30 days or about 720 hours. Equivalent 
equipment was used for the second and third sets of HCH cell 
samples. However, it is noted that different transmission com-
ponents (e.g., antennae) were utilized between the first and 
20 second experiments. 
These results were indicative of varying cellular effects due 
to substantive differences in the B-Field magnitudes with 
respect to the second and third time-varying stimulation fields 
as well as between the first and second time-varying stimu- 
25 lation fields. Hence, the results of the second experiment 
were, on its face, consistent with consensus related art pub-
lications that described a B-Field magnitude as comprising 
the determinative control factor for cellular effects. In other 
words, as can be observed in Table 4 and Table 2 (as compared 
30 to Table 4), there are substantive differences in the resultant 
gene expressions between human chondrocyte cellular expo-
sure to the second and third time-varying stimulation fields as 
well as between the first and second time-varying stimulation 
fields. For example, the total number of regulated genes 
35 between the first and second time-varying stimulation fields 
(2021 vs. 1097) constituted a 46% decrease in regulated 
genes. It was not anticipated that such a substantive decrease 
in regulated genes would occur. Rather, because consensus 
related art publications disclose that a B-Field magnitude is 
40 the determinative control value and a high enough B-Field 
magnitude is required to stimulate cellular effects, it was 
anticipated that the total number of regulated genes would 
increase. The inventors hypothesized that the substantive 
decrease in regulated genes was related to the fact that differ- 
45 ent transmission components were used in regard to the first 
and second experiments. In terms of net effects, the results of 
the second experiment validated the inventors' observations 
in regard to anabolic vs. catabolic effects associated with the 
second time-varying stimulation field. Table 3 represents a 
50 summary of the second experiment in regard to gene expres-
sion. 
TABLE 3 
55 	 Stimulation Field 
# Genes 
Regulated 
# of Anabolic 
Gene Effects* 
# of Catabolic 
Gene Effects* 
Second Time- 1097 52 3 
Varying 
Stimulation Field 
Third Time- 850 12 15 
60 Varying 
Stimulation Field 
*In exemplary results in accordance to Table 4 
As can be observed in Table 3, when taking into account the 
65 exemplary results in accordance to Table 4, the anabolic and 
catabolic effects associated with the second and third time- 
varying stimulation fields are substantively different. Yet 
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there is a commonality between the first and second stimula-
tion fields or specifically, the disproportionally large number 
of anabolic vs. catabolic gene responses. The exemplary 
results for the second time-varying stimulation field are 
indicative of anabolic or regenerative effects. Conversely, the 
exemplary results from the third time-varying stimulation 
field are relatively neutral in regard to anabolic vs. catabolic 
26 
effects while the total B-Field is much higher (65 µT vs. 250 
µT). This result is not expected given prior art publications 
and was therefore unanticipated. Specifically there should be 
much greater effects at 250 µT as compared to 65 µT, however 
5 this was not the case. A comparison of the exemplary results 
associated with the two field profiles are provided in Table 4 
below: 
TABLE 4 
Gene Family 
Fold 
Increase/ 
Decrease for 
Second Time 
Varying 
Stimulation 
Field 
Anabolic or 
Catabolic 
Effect of 
Genes 
Associated 
with Chondrocyte 
Development 
Fold 
Increase/ 
Decrease for 
Third Time 
Varying 
Stimulation 
Field 
Anabolic or 
Catabolic 
Effect of 
Genes 
Associated 
with Chondrocyte 
Development 
WNT Family 
WNTSB +00.0 NDR -3.43 Catabolic 
WSP1 +00.0 NDR +3.25 Anabolic 
WSP2 +00.0 NDR -2.91 Catabolic 
Bone Morphogenetic Protein 
(BMP) Family 
BAMBI +5.03 Anabolic +2.95 Anabolic 
BMPI +3.32 Anabolic -3.98 Catabolic 
BMP6 +2.95 Anabolic +00.0 NDR 
Forkhead Box (FOX) Family 
FOXQI -4.69 Catabolic +00.0 NDR 
FOXN3 -3.61 Catabolic +00.0 NDR 
FOXCI +00.0 NDR -3.32 Catabolic 
Sex Determining Region  
(SRY) SOX Family 
SOX4 (SRY-box4) +2.91 Anabolic +2.91 Anabolic 
SOX9 (SRY-box9) +00.0 NDR -4.66 Catabolic 
Parathyroid Hormone (PTH) 
Family 
PTHLH (PTH-like hormone +4.03 Catabolic -6.59 Anabolic 
[LH]) 
Transforming Growth Factor 
(TGF) Family 
TGF-Beta 1 +3.03 Anabolic +00.0 NDR 
TGF-Beta 2 +4.41 Anabolic +00.0 NDR 
Latent TGF Beta Binding +4.26 Anabolic +2.89 Anabolic 
Protein 3 
Integrin Family (Cell Sur: 
ECM) 
Integrin Alpha 8 (ITGA8) +9.99 Anabolic +00.0 NDR 
Integrin Alpha 4 (ITGA4); +4.41 Anabolic +00.0 NDR 
CD49D) 
Integrin Alpha 6 0.00 NDR +3.23 Anabolic 
ITGA6 
Integrin Beta 3 (ITGB3) +3.63 Anabolic +00.0 NDR 
Integrin Beta 2 (ITGB2) +3.71 Anabolic +00.0 NDR 
Integrin Alpha 2 (ITGA2); +3.34 Anabolic +00.0 NDR 
CD49B 
Integrin beta-like 1 (ITGBLI) +5.46 Anabolic +00.0 NDR 
with epidermal growth 
factor (EGF)-like repeat 
domains 
Interleukin Family (Cellular 
Cytokine Response) 
Interleukin 33 (IL-33)(IL-1 +8.74 x 106 Anabolic +00.0 NDR 
super family) 
Interleukin 26 (IL-26)(IL-10 +4.59 Anabolic +00.0 NDR 
Family) 
Interleukin 8 (IL-8) +4.82 Anabolic +00.0 NDR 
Interleukin 6 (IL-6) +2.89 Anabolic +00.0 NDR 
Interleukin (IL-11) 0.00 NDR -2.91 Catabolic 
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TABLE 4-continued 
Gene Family 
Fold 
Increase/ 
Decrease for 
Second Time 
Varying 
Stimulation 
Field 
Anabolic or 
Catabolic 
Effect of 
Genes 
Associated 
with Chondrocyte 
Development 
Fold 
Increase/ 
Decrease for 
Third Time 
Varying 
Stimulation 
Field 
Anabolic or 
Catabolic 
Effect of 
Genes 
Associated 
with Chondrocyte 
Development 
Thrombospondin Family 
Thrombospondin 1 (THBS1) +4.61 Anabolic +00.0 NDR 
Thrombospondin 2 (THBS2) +3.73 Anabolic +00.0 NDR 
ADAM metallopeptidase +3.18 Anabolic -3.72 Catabolic 
with thrombospondin type 
1 motif (ADAMTS 1) 
ADAM metallopeptidase +4.00 Anabolic -2.89 Catabolic 
with thrombospondin type 
5 motif (ADAMTS5) 
Laminin Family 
Laminin Beta 1 (LAMBI) +00.0 NDR +3.78 Anabolic 
Proteoglycan Family 
Biglycan (BGN) +3.46 Anabolic +00.0 NDR 
Aggrecan (ALAN) +3.81 Anabolic +00.0 NDR 
PAPLN (Papilin) +00.0 NDR +4.79 Anabolic 
Hyalmonan and +5.03 Anabolic +00.0 NDR 
Proteoglycan Link protein 1 
(HAPLN 1) 
Proteoglycan 4 (PRG4) +3.76 Anabolic +00.0 NDR 
Leucine Proline-enriched +2.91 Anabolic +00.0 NDR 
Proteoglycan (Leprecan- 
Like) 1 (LEPREI) 
Matrix Metallapeptidase 
(MMP) Family 
SMMPI (interstitial -3.39 Anabolic +5.50 Catabolic 
collagenase) 
MMP3 (interstitial -2.89 Anabolic +3.18 Catabolic 
collagenase) stromelysin 1 
MMP13 (interstitial -3.97 Anabolic +4.41 Catabolic 
collagenase 3) 
Tissue Inhibitor of 
Metalloproteinases (TIMP) 
Family 
TIMP Inhibitor 3 (TIMP3) +3.03 Anabolic -4.03 Catabolic 
(Sorsby Fundus Dystrophy) 
Collagen Family 
Collagen, Type 1, Alpha 1 +32.62 Anabolic +5.98 Anabolic 
(COL1A1) 
Collagen, Type 3, Alpha 1 +4.23 Anabolic +3.84 Anabolic 
(COL3A1) 
Collagen, Type 4, Alpha 1 +2.95 Anabolic +00.0 NDR 
(COL4A1) 
Collagen, Type 4, Alpha 2 +3.12 Anabolic +00.0 NDR 
(COL4A2) 
Collagen, Type 4, Alpha 4 +5.06 Anabolic +00.0 NDR 
(COL4A4) 
Collagen, Type 5, Alpha 1 +22.62 Anabolic +00.0 NDR 
(COL5A1) 
Collagen, Type 11, Alpha 1 +44.63 Anabolic +00.0 NDR 
(COL11A1) (Cartilage) 
Collagen, Type 12, Alpha 1 +3.92 Anabolic +00.0 NDR 
(COL12A1) 
Collagen, Type 15, Alpha 1 +22.47 Anabolic -9.71 Catabolic 
(COL15A1) (Muscle and 
Microvascular Deterio) 
Collagen, Type 21, Alpha 1 +00.0 NDR +5.06 Anabolic 
(COL21A1) 
Collagen, Type 27, Alpha 1 +00.0 NDR +5.06 Anabolic 
(COL27A1) 
Insulin Family 
Insulin-Like Growth Factor 0.00 NDR +3.94 Anabolic 
(IGF) 1 (IGFI) 
Insulin-Like Growth Factor +4.76 Anabolic +4.29 Anabolic 
(IGF) 2 (IGF2) 
28 
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TABLE 4-continued 
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Fold Anabolic or Fold Anabolic or 
Increase/ Catabolic Increase/ Catabolic 
Decrease for Effect of Decrease for Effect of 
Second Time Genes Third Time Genes 
Varying Associated Varying Associated 
Stimulation with Chondrocyte Stimulation with Chondrocyte 
Gene Family Field Development Field Development 
IGF Binding Protein (IGFBP) +7.78 Anabolic -52.35 Catabolic 
1 
IGFBP2 +13.45 Anabolic -00.0 NDR 
IGFBP3 +10.70 Anabolic -3.07 Catabolic 
IGFBPS +2.81 Anabolic -5.74 Catabolic 
IGFBP6 0.00 NDR -3.05 Catabolic 
Actin Family 
Actin, Alpha 2 (ACTH) 2 +3.32 Anabolic +00.0 NDR 
Actinin, Alpha 1 (ACTNI) +3.12 Anabolic +00.0 NDR 
Palladin Cytoskeletal +3.23 Anabolic +00.0 NDR 
Associated Protein (PALLD) 
Actin/Cytoskeletal Related 
Genes 
Cytoskeleton-Associated +2.85 Anabolic +00.0 NDR 
Protein (CKAP) 4 
Catenin (Cadherin- +3.81 Anabolic +00.0 NDR 
Associated Protein, Alpha 1) 
(CTNNAI) 
Cadherin 2, N-Cadherin +16.45 Anabolic +00.0 NDR 
(Neuronal) (CDH2) 
H-Cadherin (Heart) (CDH13) +3.27 Anabolic -2.99 Catabolic 
Filamin B, Beta (Actin +2.95 Anabolic +00.0 NDR 
Binding Protein 278) (FLNB) 
Filamin C, Gamma (Actin +00.0 NDR -2.93 Catabolic 
Binding Protein 280) (FLNC) 
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As can be observed in Table 4, several select genes of 
interest experienced up or down-regulation in the second 
experiment. It is noted that ADAMTS genes are generally 
considered to be anabolic when up-regulated but catabolic 
when down-regulated. As can be observed in Table 4, 
ADAMTSI and 5 were both up-regulated with respect to 
exposure to the second time-varying stimulation field. Con-
versely, ADAMTSI and 5 were down-regulated with respect 
to exposure to the third time-varying stimulation field. MMPs 
proteases are generally considered catabolic because they 
break down tissue (a process associated with remodeling and 
repair). When MMPs are down-regulated, catabolic effects 
are suppressed thereby having in a net anabolic effect. Con-
versely, when MMPs are up-regulated their catabolic effects 
are enhanced. As can be observed in Table 4, MMPI, 3, and 13 
were down-regulated with respect to exposure to the second 
time-varying stimulation field. Conversely, MMP 1, 3, and 13 
were up-regulated with respect to exposure to the third time-
varying stimulation field. The functionality of BMPs was 
discussed above. With particular reference to BMPL it is a 
metalloprotease that acts on procollagen I, II, and Ill. BMPI 
is involved in cartilage development and is related to a regen-
erative function or anabolic in nature. As can be observed in 
Table 4, BMPI was up-regulated with respect to exposure to 
the second time-varying stimulation field. Conversely, BMPI 
was down-regulated with respect to exposure to the third 
time-varying stimulation field. 
Example 3 
Human Osteoblasts 
In a third experiment, a first set of HOB cell samples 
contained in at least 3 RWVs were exposed to substantially  
the same time-varying stimulation field profile as compared 
to the second time-varying stimulation field of predetermined 
35 profile in the second experiment. For clarity purposes, this 
stimulation field profile will be referred to as a fourth time- 
varying stimulation field of predetermined profile comprised 
of substantially a biphasic, square wave with a frequency of 
about 10 Hz; a wavelength of about 500 ms; a rising slew rate 
40 between about 0.2 T/s (2.0 kG/s) to about 0.45 T/s (4.5 kG/s); 
a falling slew rate between about 0.45 T/s (4.5 kG/s) to about 
1.55 T/s (15.5 kG/s); a dwell time of about 10% after each 
burst; a duty cycle of about 80% on and about 20% off; and a 
45 resultant B-Field magnitude of about 65 µT (0.65 G). A sec- 
ond set of HOB cell samples contained in at least 3 RWVs 
were also separately exposed to substantially the same stimu- 
lation field as compared to the third time-varying stimulation 
field previously described. For clarity purposes, this pulsed 
50 stimulation field will be referred to as the fifth time-varying 
stimulation field of predetermined profile comprised substan- 
tially of a monophasic, delta wave with a frequency of 15 Hz; 
a duty cycle of about 30% on and about 70% off, and a 
resultant B-Field magnitude of about 65 µT (0.65 G), wherein 
55 said B-Field magnitude is substantially fixed in one direction 
(i.e., monophasic). Note that in this experiment, the B-Field 
magnitudes of the fourth and fifth time-varying stimulation 
fields were substantially equal. Equivalent equipment was 
used for the first and second sets of HOB cell samples. It is 
6o also noted that equivalent equipment was used in comparison 
with the second and third experiments. Exposures were con- 
tinuous for the length of this experiment wherein said length 
was about 30 days or about 720 hours. As in the second 
experiment, the resultant cellular effects between the first and 
65 second sets of HOB cell samples were substantively different. 
It is noted here that two separate gene analyses for the first and 
second set of HOB cell samples were conducted. For the first 
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set of HOB cell samples, these gene analyses are defined as #1 TABLE 5-continued 
and #2 Fold Increase/Decrease for Fourth Time Varying 
Stimulation Field in Tables 6 and 7 below. For the second set # Genes 	 # ofAnabolic 	 # of catabolic 
of HOB cell samples, these gene analyses are defined as #3 Stimulation Field Regulated 	 Gene Effects- 	 Gene Effects - 
and #4 Fold Increase/Decrease for Fifth Time Varying Stimu- 5 
lation Field in Tables 6 and 7 below. A comparison of exem- #2 Fourth Time- 2691 	 81 	 4 
plary results associated with the two separate gene analyses varying 
for each of the two field profiles are provided in the tables Stimulation Field 
below: #3 Fifth Time- 437 	 20 	 7 
10 varying 
TABLE 5 Stimulation Field 
# Genes 	 # of Anabolic 	 # of Catabolic #4 Fifth Time- 527 	 21 	 5 
Stimulation Field 	 Regulated 	 Gene Effects 	 Gene Effects Varying 
Stimulation Field 
#1 Fourth Time- 	 2495 	 87 	 6 15 
Varying 
Stimulation Field In exemplary results in accordance to Tables 6 and 7. 
TABLE 6 
Anabolic or Anabolic or 
Catabolic Catabolic 
Effect Effect Effect Effect 
#1 Fold of Genes #3 Fold of Genes 
Increase/Decrease Associated Increase/Decrease Associated 
for Fourth Time with Osteoblast for Fifth Time with Osteoblast 
Varying and bone cell varying and bone cell 
Gene Family Stimulation Field Development Stimulation Field Development 
actin (ACTS) NDR NRE +3.3309 Anabolic 
ADAM metallopeptidase +4.0239 Anabolic +3.1776 Anabolic 
domain 10 (ADAM10) 
ADAM metallopeptidase +3.1086 Anabolic NDR NRE 
domain 17 (tumor 
necrosis factor interacts 
with TNT alpha 
(ADAM17) 
ADAM metallopeptidase +9.6955 Anabolic NDR NRE 
with thrombospondin 
type 1 motif (ADAMTSI) 
apoptosis inhibitor 5 +2.9426 Anabolic NDR NRE 
(AP15) 
B-cell CLL/lymphoma 3 +2.9013 Anabolic NDR NRE 
(BCL3) 
B-cell CLL/lymphoma 6 NDR NRE +2.8595 Anabolic 
(zinc finger protein 51) 
(BCL6) 
BCL2-associated NDR NRE +2.8730 Anabolic 
athanogene 2 (BAG2) 
BCL2-related protein At -3.2422 Catabolic NDR NRE 
(BCL2A1) 
biglycan (BGN) +17.3408 Anabolic NDR NRE 
(201262_s_at) 
bone morphogenetic +136.2100 Anabolic NDR NRE 
protein 2 (BMP2) 
bone morphogenetic +3.2517 Anabolic NDR NRE 
protein receptor 
(BMPR2) 
cadherin 11 Bone +3.4967 Anabolic NDR NRE 
Specific/Osteoblasts 
(CDHI I) 
Calcium/calmodulin- +6.0076 Anabolic NDR NRE 
dependent protein 
kinase (CaM kinase) 
delta (CAMK2D) 
calmodulin 1 NDR NRE +2.9689 Anabolic 
(phosphorylase kinase 
(CALMI) 
calumenin (CALU) +4.0815 Anabolic +3.5804 Anabolic 
(214845_s_at) 
cartilage oligomeric +12.1656 Anabolic -3.8106 Catabolic 
matrix protein (COMP) 
CASP8 and FADD-like -2.8575 Anabolic NDR NRE 
apoptosis regulator 
(CFLAR) 
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TABLE 6-continued 
Gene Family 
#1 Fold 
Increase/Decrease 
for Fourth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
#3 Fold 
Increase/Decrease 
for Fifth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
catenin (cadherin- +4.4593 Anabolic +3.2564 Anabolic 
associated protein) 
(CTNNB I ) 
cathepsin C (CTSC) -4.2881 Anabolic NDR NRE 
cathespin O (CTSO) -2.8365 Anabolic NDR NRE 
cathespin S (CTSS) -2.9715 Anabolic NDR NRE 
chondroitin sulfate +4.0672 Anabolic NDR NRE 
proteoglycan 4 (CSPG4) 
(214297_at) 
clusterin Anti apoptosis +19.4810 Anabolic NDR NRE 
and MMPs (CLU) 
collagen (COL12A1) +2.9218 Anabolic NDR NRE 
collagen (COL15A1) -16.2926 Anabolic NDR NRE 
collagen (COL1A1) +2.8683 Anabolic NDR NRE 
collagen (COL3A1) +4.7532 Anabolic NDR NRE 
collagen (COL3A1) +4.5715 Anabolic NDR NRE 
collagen (COL4A1) +3.1465 Anabolic NDR NRE 
collagen (COL4A2) +3.2012 Anabolic +2.8581 Anabolic 
collagen (COL4A3BP) +3.3796 Anabolic NDR NRE 
collagen (COL5A2) +3.6551 Anabolic NDR NRE 
collagen (COL6A1) +3.0345 Anabolic +3.2741 Anabolic 
collagen (COL8A1) +2.9195 Anabolic NDR NRE 
cytochrome P450 +6.4062 Anabolic +3.7186 Anabolic 
(CYP1B1) embryonic 
development 
cytochrome P450 +5.0863 Anabolic NDR NRE 
(CYP24AI) Vit D3 
homeostatis 
endoglin (Osler-Rendu- NDR NRE +2.9135 Catabolic 
Weber syndrome 1) 
(ENG) 
Fas (TNF receptor +3.2724 Anabolic +3.5713 Anabolic 
superfamily (FAS) 
fibrillin 1 (FBNI) +3.2809 Anabolic +3.7335 Anabolic 
fibroblast growth factor -2.8473 Anabolic NDR NRE 
1 (acidic) (FGFI) 
fibroblast growth factor +4.5734 Anabolic NDR NRE 
18/ embryonic 
development, cell 
growth, morphogenesis, 
tissue repair (FGF18) 
fibulin 1 (FBLNI) +4.1863 Anabolic NDR NRE 
forkhead box N3 (FOXN3) +3.9116 Anabolic NDR NRE 
forkhead box 01 +2.8822 Anabolic NDR NRE 
(FOXOI) 
forkhead box 03 Tumor +3.3640 Anabolic NDR NRE 
Suppressor (FOXO3) 
(204132_s_at) 
forkhead box 03 +3.1184 Anabolic NDR NRE 
(FOXO3) (210655_s_at) 
forkhead box Q1 +3.3091 Anabolic NDR NRE 
Function Unknown 
(FOXQI) 
importin 11 (IPOII) +2.9481 Anabolic NDR NRE 
importin 7 (IPO7) +4.7592 Anabolic NDR NRE 
(200992_at) 
insulin-like growth factor +3.1870 Anabolic NDR NRE 
1 (somatomedin C) 
(IGF1) 
insulin-like growth factor -13.6898 Anabolic NDR NRE 
binding protein 1 
(IGFBPI) 
insulin-like growth factor -18.5362 Anabolic NDR NRE 
binding protein 5 
(IGFBPS) 
interleukin 1 family NDR NRE +4.1682 Catabolic 
(IL1F8) 
interleukin 17D (IL17D) -2.8729 Anabolic NDR NRE 
interleukin 32 (IL32) +2.8646 Anabolic NDR NRE 
34 
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TABLE 6-continued 
Gene Family 
#1 Fold 
Increase/Decrease 
for Fourth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
#3 Fold 
Increase/Decrease 
for Fifth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
interleukin 33 (IL33) +48.2994 Anabolic +3.2614 Anabolic 
interleukin 6 (interferon -3.7429 Anabolic NDR NRE 
(IL6) 
interleukin 8 (IL8) +3.0542 Anabolic +3.6065 Anabolic 
laminin (LAMBI) +2.9398 Anabolic -2.9140 Catabolic 
leptin (obesity homolog -2.8863 Anabolic NDR NRE 
(LEP) 
matrix metallopeptidase NDR NRE +2.8543 Catabolic 
14 (membrane-inserted) 
(MMP14) 
mitogen-activated +3.6457 Anabolic NDR NRE 
protein kinase associated 
protein 1 (MAPKAPI) 
mitogen-activated +8.9929 Anabolic NDR NRE 
protein kinase-activated 
protein kinase 2/ 
inhibition of apoptosis, 
regulation of cell 
development, and cell 
differentiation 
(MAPKAPK2) 
rush homeobox 1 (MSXI) +3.4459 Anabolic NDR NRE 
Notch homolog 2 +5.1985 Anabolic +3.6551 Anabolic 
(Drosophila) (NOTCH2) 
nuclear factor of +4.0922 Anabolic NDR NRE 
activated T-cells 
(NFATC3) 
osteoglycin (OGN) +3.2508 Anabolic NDR NRE 
pallidin homolog (mouse) +2.9546 Anabolic NDR NRE 
(PLDN) 
parathyroid hormone- -3.9816 Catabolic NDR NRE 
like hormone (PTHLH) 
peroxisome proliferator- +3.7661 Anabolic NDR NRE 
activated receptor alpha 
(PPARA) 
platelet derived growth +11.8582 Anabolic +3.7643 Anabolic 
factor C (PDGFC) 
procollagen-lysine +3.1194 Anabolic NDR NRE 
(PLOD2) 
procollagen-proline +3.1958 Anabolic +3.3121 Anabolic 
(P4HB) 
protocadherin beta 6 +3.5486 Anabolic NDR NRE 
(PCDHB6) 
protocadherin gamma +3.1857 Anabolic NDR NRE 
subfamily A (PCDHGA3) 
reticulocalbin 1 (RCNI) -2.8536 Anabolic NDR NRE 
runt-related +4.2303 Anabolic NDR NRE 
transcription factor 2 
(RUNX2) 
signal transducer and -4.7015 Anabolic +3.0161 Catabolic 
activator of transcription 
1 (STATI) 
signal transducer and -3.1518 Anabolic NDR NRE 
activator of transcription 
2 (STAT2) 
signal transducer and +2.9537 Anabolic NDR NRE 
activator of transcription 
3 (acute-phase response 
factor) (STAT3) 
SMAD family member 1 +2.9000 Anabolic NDR NRE 
(SMADI) 
SMAD family member 2 +2.9848 Anabolic NDR NRE 
(SMAD2) 
SMAD family member 4 +4.8768 Anabolic +2.9077 Anabolic 
(SMAD4) 
SMAD family member 6 +3.6075 Anabolic NDR NRE 
(SMAD6) 
spare/osteonectin +3.3007 Anabolic NDR NRE 
(SPOCKI) 
36 
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TABLE 6-continued 
Anabolic or Anabolic or 
Catabolic Catabolic 
Effect Effect Effect Effect 
#1 Fold of Genes #3 Fold of Genes 
Increase/Decrease Associated Increase/Decrease Associated 
for Fourth Time with Osteoblast for Fifth Time with Osteoblast 
Varying and bone cell Varying and bone cell 
Gene Family Stimulation Field Development Stimulation Field Development 
SRY (sex determining +6.0198 Anabolic NDR NRE 
region Y)-box 4 (SOX4) 
(201417_at) 
SRY (sex determining +2.9461 Anabolic NDR NRE 
region Y)-box 9 
(campomelic dysplasia 
(SOX9) 
stanniocalcin 1 (STCI) —133.3427 Anabolic NDR NRE 
stanniocalcin 2 (STC2) —6.3031 Anabolic —2.8380 Anabolic 
superoxide dismutase 2 +4.1182 Anabolic NDR NRE 
(SOD2) 
syndecan 1 (SDCI) +2.8761 Anabolic NDR NRE 
TRAF family member- +2.9982 Anabolic NDR NRE 
associated NFKB 
activator (TANK) 
tumor necrosis factor —5.8708 Anabolic NDR NRE 
(ligand) superfamily 
TRAIL (TNFSFIO) 
tumor necrosis factor —3.9019 Anabolic +3.3676 Catabolic 
(ligand) superfamily 
(TNFSFI3B) 
tumor necrosis factor —13.4107 Anabolic NDR NRE 
(ligand) superfamily 
(TNFSFIS) 
tumor necrosis factor NDR NRE —2.9040 Anabolic 
receptor superfamily 
(TNFRSFIOD) 
v-akt murine thymoma +4.3325 Anabolic NDR NRE 
viral oncogene homolog 
3 (protein kinase B 
(AKT3) 
TABLE 7 
Anabolic or Anabolic or 
Catabolic Catabolic 
Effect Effect Effect Effect 
#2 Fold of Genes #4 Fold of Genes 
Increase/Decrease Associated Increase/Decrease Associated 
for Fourth Time with Osteoblast for Fifth Time with Osteoblast 
Varying and bone cell Varying and bone cell 
Gene Family Stimulation Field Development Stimulation Field Development 
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actin (ACTB) 
ADAM metallopeptidase 
domain 10 (ADAM10) 
ADAM metallopeptidase 
domain 17 (tumor 
necrosis factor 
(ADAM17) 
ADAM metallopeptidase 
domain 33 (ADAM33) 
ADAM metallopeptidase 
with thrombospondin 
type 1 motif (ADAMTSI) 
ADAM metallopeptidase 
with thrombospondin 
type 1 motif (ADAMTS6) 
B-cell CLL/lymphoma 6 
(zinc forger protein 51) 
(BCL6) 
biglycan (BGN) 
bone gamma-
carboxyglutamate (gla) 
protein (osteocalcin) 
(BGLAP) 
bone morphogenetic 
protein 2 (BMP2) 
NDR 	 NRE 	 +3.2497 	 Anabolic 
+3.8784 	 Anabolic 	 +3.1870 	 Anabolic 
+3.0926 	 Anabolic 	 +3.1296 	 Anabolic 
—5.5601 Catabolic NDR NRE 
+4.3910 Anabolic NDR NRE 
—2.9113 Catabolic NDR NRE 
+4.2264 Anabolic +2.9836 Anabolic 
+10.8190 Anabolic NDR NRE 
+3.4068 Anabolic NDR NRE 
+265.1634 Anabolic NDR NRE 
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TABLE 7-continued 
Gene Family 
#2 Fold 
Increase/Decrease 
for Fourth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
#4 Fold 
Increase/Decrease 
for Fifth Time 
Varying 
Stimulation Field 
Anabolic or 
Catabolic 
Effect Effect 
of Genes 
Associated 
with Osteoblast 
and bone cell 
Development 
calcium/calmodulin- +4.2280 Anabolic NDR NRE 
dependent protein 
kinase (CaM kinase) 
delta (CAMK2D) 
calmodulin 1 NDR NRE +2.9379 Anabolic 
(phosphorylase kinase 
(CALMI) 
calumenin (CALU) +3.2043 Anabolic +3.1993 Anabolic 
cartilage oligomeric +17.7007 Anabolic -4.0956 Catabolic 
matrix protein (COMP) 
catenin (cadherin- +4.5090 Anabolic +3.5238 Anabolic 
associated protein) 
(CTNNB I ) 
cathepsin C (CTSC) -4.9355 Anabolic NDR NRE 
cathepsin H (CTSH) -3.1342 Anabolic NDR NRE 
cathepsin S (CTSS) -2.8325 Anabolic NDR NRE 
chondroitin sulfate +3.2199 Anabolic NDR NRE 
proteoglycan 4 (CSPG4) 
clusterin (CLU) +26.2849 Anabolic NDR NRE 
collagen (COL12A1) +3.6143 Anabolic +2.9117 Anabolic 
collagen (COL16A1) -2.8512 Anabolic -3.0354 Anabolic 
collagen (COL1A1) +2.8438 Anabolic NDR NRE 
collagen (COL3A1) +5.4512 Anabolic NDR NRE 
collagen (COL4A2) +3.0110 Anabolic NDR NRE 
collagen (COL5A2) +2.9639 Anabolic NDR NRE 
cytochrome P450 -2.9175 Anabolic NDR NRE 
(CYP11A1) 
cytochrome P450 -11.9176 Anabolic NDR NRE 
(CYP19A1) 
cytochrome P450 +7.1220 Anabolic +4.4823 Anabolic 
(CYP1B1) 
cytochrome P450 +5.3640 Anabolic NDR NRE 
(CYP24A1) 
cytochrome P450 -2.9432 Anabolic NDR NRE 
(CYP4V2) 
cytochrome P450 +4.7959 Anabolic NDR NRE 
(CYP51A1) 
cytochrome P450 -4.6752 Anabolic NDR NRE 
(CYP7B1) 
endoglin (Osler-Rendu- +2.9055 Catabolic NDR NRE 
Weber syndrome 1) 
(ENG) 
Fas (TNF receptor +3.0606 Anabolic NDR NRE 
superfamily (FAS) 
fibrillin 1 (FBNI) +3.3971 Anabolic +3.6475 Anabolic 
fibroblast growth factor -2.9045 Anabolic NDR NRE 
1 (acidic) (FGFI) 
fibroblast growth factor +6.0853 Anabolic NDR NRE 
18 (FGF18) embryonic 
development 
fibulin 1 (FBLNI) +4.8829 Anabolic NDR NRE 
forkhead box Q1 +3.2639 Anabolic NDR NRE 
(FOXQI) 
importin 11 (IPOII) +3.5238 Anabolic NDR NRE 
importin 7 (IPO7) +4.7773 Anabolic NDR NRE 
insulin-like growth factor +2.9529 Anabolic NDR NRE 
1 (somatomedin C) 
(IGF1) 
insulin-like growth factor -11.3487 Anabolic NDR NRE 
binding protein 1 
(IGFBPI) 
insulin-like growth factor -3.4126 Anabolic NDR NRE 
binding protein 2 
(IGFBP2) 
interleukin 1 family NDR NRE +4.6908 
(IL1F8) 
interleukin 32 (IL32) +2.8329 Anabolic NDR NRE 
interleukin 33 (IL33) +77.4903 Anabolic +3.4328 Anabolic 
interleukin 4 induced 1 -2.9266 Anabolic NDR NRE 
(IL4I1) 
40 
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TABLE 7-continued 
Anabolic or Anabolic or 
Catabolic Catabolic 
Effect Effect Effect Effect 
#2 Fold of Genes #4 Fold of Genes 
Increase/Decrease Associated Increase/Decrease Associated 
for Fourth Time with Osteoblast for Fifth Time with Osteoblast 
Varying and bone cell Varying and bone cell 
Gene Family Stimulation Field Development Stimulation Field Development 
interleukin 6 (interferon -4.0698 Anabolic NDR NRE 
(IL6) 
interleukin 8 (IL8) NDR NRE +4.4075 Anabolic 
laminin (LAMBI) +3.5168 Anabolic NDR NRE 
leptin (obesity homolog -2.8432 Anabolic NDR NRE 
(LEP) 
mitogen-activated +3.4504 Anabolic NDR NRE 
protein kinase associated 
protein 1 (MAPKAPI) 
mitogen-activated +6.6319 Anabolic +3.4968 Anabolic 
protein kinase-activated 
protein kinase 2 
(MAPKAPK2) 
rush homeobox 1 (MSXI) +3.1872 Anabolic NDR NRE 
Notch homolog 2 +6.6681 Anabolic +3.9031 Anabolic 
(Drosophila) (NOTCH2) 
nuclear factor of +4.4679 Anabolic NDR NRE 
activated T-cells 
(NFATC3) 
osteoglycin (OGN) +2.9048 NDR NRE 
pallidin homolog (mouse) +3.7839 NDR NRE 
(PLDN) 
parathyroid hormone- -2.9471 Anabolic NDR NRE 
like hormone (PTHLH) 
peroxisome proliferator- +3.3980 Anabolic NDR NRE 
activated receptor alpha 
(PPARA) 
platelet derived growth +8.6547 Anabolic NDR NRE 
factor C (PDGFC) 
(222719_s_at) 
platelet-derived growth +2.8343 Anabolic NDR NRE 
factor alpha polypeptide 
(PDGFA) 
procollagen-lysine +3.2120 Anabolic NDR NRE 
(PLOD2) 
procollagen-proline +3.3854 Anabolic +3.2322 Anabolic 
(P4HB) 
protocadherin 7 (PCDH7) +4.3290 Anabolic NDR NRE 
protocadherin beta 15 +3.1245 Anabolic NDR NRE 
(PCDHBIS) 
protocadherin beta 5 +4.9055 Anabolic NDR NRE 
(PCDHBS) 
protocadherin gamma +3.6665 Anabolic +3.1682 Anabolic 
subfamily A (PCDHGAIO/// 
PCDHGAI I/// 
PCDHGAI2/// 
PCDHGA3/// 
PCDHGAS/// 
PCDHGA6) 
protocadherin gamma +3.2147 Anabolic NDR NRE 
subfamily C (PCDHGC3) 
runt-related +4.6912 Anabolic NDR NRE 
transcription factor 2 
(RUNX2) 
signal transducer and -5.6924 Anabolic +3.5656 Catabolic 
activator of transcription 
1 (STATI) 
signal transducer and -3.1503 Anabolic +3.3033 Catabolic 
activator of transcription 
2 (STAT2) 
signal transducer and +2.8810 Anabolic +2.8416 Anabolic 
activator of transcription 
3 (acute-phase response 
factor) (STAT3) 
SMAD family member 2 +2.9680 Anabolic NDR NRE 
(SMAD2) 
SMAD family member 4 +4.4233 Anabolic +3.2649 Anabolic 
(SMAD4) 
SMAD family member 6 +3.8208 Anabolic NDR NRE 
(SMAD6) 
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TABLE 7-continued 
Anabolic or Anabolic or 
Catabolic Catabolic 
Effect Effect Effect Effect 
#2 Fold of Genes #4 Fold of Genes 
Increase/Decrease Associated Increase/Decrease Associated 
for Fourth Time with Osteoblast for Fifth Time with Osteoblast 
Varying and bone cell varying and bone cell 
Gene Family Stimulation Field Development Stimulation Field Development 
SMAD family member 7 +3.4806 Anabolic NDR NRE 
(SMAD7) 
spare/osteonectin +3.2869 Anabolic NDR NRE 
(SPOCKI) 
SRY (sex determining +3.6585 Anabolic NDR NRE 
region Y)-box 4 (SOX4) 
SRY (sex determining +2.8642 Anabolic NDR NRE 
region Y)-box 9 
(campomelic dysplasia 
(SOX9) 
stanniocalcin 1 (STCI) —76.1478 Anabolic NDR NRE 
stanniocalcin 2 (STC2) —7.3838 Anabolic NDR NRE 
superoxide dismutase 2 +3.6248 Anabolic NDR NRE 
(SOD2) 
syndecan 1 (SDCI) +3.0232 Anabolic NDR NRE 
TIMP metal lopeptidase NDR NRE +2.8771 Anabolic 
inhibitor 3 (Sorsby 
fundus dystrophy 
(TIMP3) 
tumor necrosis factor —3.1995 Anabolic NDR NRE 
(ligand) superfamily 
BAFF (TNFSFI3B) 
tumor necrosis factor —3.2316 Anabolic +3.6523 Catabolic 
(ligand) superfamily 
TRAIL (TNFSFlO 
tumor necrosis factor +2.8649 Anabolic NDR NRE 
receptor superfamily 
(TNFRSFIOA) 
tumor necrosis factor NDR NRE —2.9102 Anabolic 
receptor superfamily 
(TNFRSFIOD) 
tumor necrosis factor —2.9260 Catabolic NDR NRE 
receptor superfamily 
(TNFRSFIIB) 
tumor necrosis factor NDR NRE +3.4511 Catabolic 
receptor superfamily 
(TNFRSF21) 
v-akt murine thymoma +4.0693 Anabolic NDR NRE 
viral oncogene homolog 
3 (protein kinase B 
(AKT3) 
44 
Based on consensus related art publications, it was antici-
pated that the results associated with the fourth and fifth 
time-varying stimulation fields would be substantially or at 
least reasonably equal given that the B-Field magnitudes 
were substantially the same. However, the actual results 
refuted this expectation. In fact, the actual results of the third 
experiment indicate that the differences in gene expressions 
were not substantially the result of B-Field magnitude. 
Rather, other FOMs related to a field's profile affect cellular 
activity wherein said other FOMs can overcome the strength 
(or lack thereof) of a B-Field magnitude. It is noted that of the 
47,000 genes analyzed, approximately 2500 genes responded 
to the fourth time-varying stimulation field as compared to 
approximately 450 genes responding to the fifth time-varying 
stimulation field which comprises a greater than 550% 
increase in gene response. The difference in the number of 
gene responses and associated percentage difference is 
indicative of the fourth time-varying stimulation field having 
a significantly greater effect on HOBS as compared to the fifth 
time-varying stimulation field. Hence, as previously dis-
cussed, the results refute the related art expectation that sub-
stantially or at least reasonably similar results were expected  
45 due to substantially similar B-Field magnitudes associated 
with the fourth and fifth time-varying stimulation fields. 
It is also noted that the same observation with regard to 
regulation of regenerative vs. reparative genes in the first and 
second experiments was made in this experiment. In sum, it 
So 
can be stated that certain types of genes and genomic cascades 
respond differently to different stimulation fields of predeter-
mined profiles. And, in regard to the fourth time-varying 
stimulation field, anabolic genes are substantially up-regu- 
55 lated as compared to other types of genes. Further, the inven-
tors realized another unanticipated result wherein the inven-
tors observed that the percentage of regulated genes 
associated with the HOB sample exposed to the fourth time-
varying stimulation field was much higher as compared to the 
60 percentage of regulated genes associated with the HCH 
sample exposed to the second time-varying stimulation field 
(note: as stated before, the second and fourth time-varying 
stimulation fields are substantially equal). In other words, the 
inventors observed that the same stimulation field of prede- 
65 termined profile affects genetic response in HCH differently 
as compared to HOB. Thus, the same stimulation field profile 
can be applied to different tissue wherein different results 
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occur. In regard to different genetic responses in HCH and 	 set of cellular samples 53; analyzing the genetic anabolic and 
compared to HOB, the inventors postulate that due to sub- 	 catabolic effects from the results of said at least one gene 
stantial differences in the total CA2+ and K+ density in car- 	 expression analyses 54; generating at least one conclusion 
tilage vs. mineralized bone, the subcellular transcription sig- 	 from said step of analyzing 55; comparing said at least one 
nals are different when exposed to the same stimulation field. 5 conclusion with predetermined criteria 65; if said at least one 
This presents an unanticipated explanation for the many dif- 	 conclusion does not meet predetermined criteria, adjusting 
ferent results seen in scientific articles using PEMFs. Thus a 	 said at least one experimental predetermined profile based on 
variety of potential tuning solutions for different mammalian 	 said at least one conclusion 56; and selecting said at least one 
tissues is likely. 	 tuned time-varying stimulation field profile for said predeter- 
Still further, the inventors realized that based on the fact 10 mined tuned exposure time or said plurality of tuned exposure 
that different stimulation fields can affect cells with regard to 	 time sequences 57. The predetermined criteria in step 56 may 
regulation of regenerative and reparative genes to produce a 	 comprise, for example, a predetermined number of anabolic 
net regenerative (i.e., anabolic) or net reparative (i.e., cata- 	 genetic effects or responses; catabolic genetic effects or 
bolic) effect, different stimulation fields and their associated 	 responses; or  combination of both. With particular reference 
exposure times or time schedules can be used in combination 15 to FIG. 10, for example, the step of analyzing the genetic 
with each other to design customized therapeutic applica- 	 anabolic and catabolic effects may be comprised of: selecting 
tions. Multiple embodiments exist for combining stimulation 	 a predetermined set of genes 58; calculating a fold change for 
fields and their associated exposure times or time schedules. 	 each gene in said set of genes from the results of said at least 
For example, in an embodiment, a stimulation field (and its 	 one gene expression 59; determining if each of said fold 
associated exposure times or time schedules) tuned to pro-  20 change is consistent with up-regulation or down-regulation 
duce a net catabolic effect in HOB cells, HCH cells, or both 	 for said each gene 60; and classifying each of said fold change 
can be initially used to stimulate a net catabolic effect. After 	 as an anabolic or catabolic effect based on said up-regulation 
a predetermined amount of catabolic or reparative effect(s) 	 or down-regulation for said each gene 61. The said step of 
are realized, another stimulation field (and its associated 	 generating at least one conclusion may be comprised of: 
exposure times or time schedules) tuned to produce a net 25 establishing a relative value for each of said anabolic or 
anabolic effect in HOB cells, HCH cells, or both can be 	 catabolic effect on said up-regulation or down-regulation for 
utilized until a predetermined amount of anabolic or regen- 	 said each gene 62; comparing each of said relative value in 
erative effect(s) are realized. The process can be repeated if so 	 combination 63; selecting a conclusion comprised of either a 
desired. Alternatively, in another embodiment, it is conceiv- 	 substantive net anabolic effect, a substantive net catabolic 
able that a therapeutic application may be customized to use 30 effect, a net anabolic effect, a net catabolic effect, or no 
a stimulation field (and its associated exposure times or time 	 determinative effect 64. 
schedules) tuned to produce a net catabolic effect in HOB 	 One skilled in the art would readily appreciate that the 
cells, HCH cells, or both in combination and simultaneously 	 present innovation is well adapted to carry out the objects and 
with a stimulation field (and its associated exposure times or 	 obtain the ends and advantages mentioned, as well as those 
time schedules) tuned to produce a net anabolic effect in HOB 35 inherent therein. The present examples along with the meth- 
cells, HCH cells, or both. Still further, the use of tuned stimu- 	 ods, procedures, treatments, and biological materials 
lation fields in series, in parallel, or both may be employed. 	 described herein are presently representative of embodiments 
The experiments discussed above and associated results 	 and preferred embodiments; are exemplary; and are not 
represent a means to tune at least one predetermined profile of 	 intended as limitations to the scope of the innovation. 
a time-varying stimulation field to preferentially stimulate 40 Changes therein and other uses will occur to those skilled in 
(up-regulate, down-regulate, or a combination of both) the 	 the art which are encompassed within the spirit of the subject 
biochemical cellular and sub-cellular molecular responses to 	 innovation as defined by the scope of the claims. 
trigger the activation of known mammalian genes responsible 
for the restoration, repair, and maintenance of cartilage and 
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bone. Specifically, said preferential stimulation can be tar-  45 
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gene families that may be targeted for preferential stimulation 50 	 Physiology, 1152. 
by a tuned time-varying stimulation field of at least one tuned 
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bolic effects, catabolic effect, or a combination of both. With 
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particular reference to FIG. 9, for example, as can be 60 	 of America. 
extracted by the sequence of experiments previously 	 Goodwin, T. J., & Parker, C. R. (2007). U.S. Pat. No. 7,179, 
described, a tuning step 50 may comprise providing at least 	 217. United States of America. 
one set of cellular samples in at least one rotating wall vessel 
	
Ishikawa, T. (2006). Steroid and Xenobiotic Receptor SXR 
51; exposing said at least one set of cellular samples to at least 	 Mediates Vitamin K2-activated Transcription of Extracel- 
one experimental time-varying stimulation field comprising 65 	 lular Matrix-related Genesand Collagen Accumulation in 
at least one experimental predetermined profile 52; conduct- 	 Osteoblastic Cells. Journal of Biological Chemistry, 
ing at least one gene expression analyses to said at least one 	 16927-16934. 
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Koshihara, Y. (1997). Vitamin K2 Enhances Osteocalcin 	 stimulation field comprised of a controlled at least one 
	
Accumulation in the Extracellular Matrix of Human 	 tuned predetermined profile; and 
	
Osteoblasts In Vitro. Journal of Bone and Mineral 	 exposing mammalian chondrocytes, osteoblasts, osteo- 
Research, 431-438. 	 cytes, osteoclasts, nucleus pulposus, associated tissue, 
	
Lanza, R. (2000). Handbook of Stem Cells. Burlington: Aca- 	 5 	 or any combination thereof to said controlled at least one 
demic Press. 	 tuned time-varying stimulation field comprised of said 
	
Nicholls, D. G., & Ferguson, S. J. (2002). Bioenergetics. 	 controlled at least one tuned predetermined profile for 
Academic Press. 	 said predetermined tuned exposure time or said plurality 
	
Nucleus pulposus. (2008, Oct. 17). Retrieved Sep. 2, 2010, 	 of tuned exposure time sequences thereby resulting in 
	
from Wikipedia: en.wikipedia.org/wiki/Nucleus_pulposus 	 10 	 said increase, decrease, or both increase and decrease in 
	
Ramsey, K. M., Marcheva, B., Kohsaka, A., & Bass, J. (2007). 	 the expression level of at least one gene or gene family 
	
The Clockwork of Metabolism. Annu. Rev. Nutr., 219-240. 	 selected from the group consisting of Writ signaling 
	
Trock, D. H. (2000). Electromagnetic Fields and Magnets: 	 family, WSP family, forkhead box (FOX) family, sex 
	
Investigational Treatment of Musculoskeletal Disorders. 	 determining region Y (SRY) SOX family, parathyroid 
Rheumatic Disease Clinics of North America, 51-62. 	 15 	 hormone (PTH) family, transforming growth factor 
(TGF) beta (TGF-(3) super family, latent TGF family 
What is claimed is: 	 (ECM), integrin family (Cell Sulfur-Based (SUR): 
	
1. A method to modulate an increase, decrease, or both 
	
ECM), interleukin (IL) family (cellular cytokine 
	
increase and decrease in the expression level of at least one 	 response), thrombospodin family (COMPS), laminin 
gene or gene family comprising the steps of: 	 20 	 family, proteoglycan family, osteoglycin, collagen fam- 
	
tuning at least one predetermined profile of at least one 	 ily, insulin family, a disintegrin and metalloproteinase 
	
time-varying stimulation field thereby resulting in at 	 (ADAM) family, ADAM with thrombospondin motifs 
	
least one tuned time-varying stimulation field comprised 
	 (ADAMTS) family, matrix metallopeptidase (MMP) 
	
of at least one tuned predetermined profile, wherein said 
	
family, actin family, catenin family, cadherin super fam- 
step of tuning is comprised of, 	 25 	 ily, B-cell lymphoma (BCL) family, calmodulin cal- 
	
providing at least one set of cellular samples in at least 	 cium-modulated gene, calumenin, cathepsin family, 
one rotating wall vessel; 	 clusterin, cytochrome P 450 super family, endoglin, 
	
exposing said at least one set of cellular samples to at 	 fibrillin family, fibroblast growth factor (FGF) family, 
	
least one experimental time-varying stimulation field 
	
leptin, MAP kinase activated protein kinases (MAP- 
	
comprising at least one experimental predetermined 	 30 	 KAP) family, MSX homeobox family, NOTCH family, 
profile; 	 myotilin-myopalladin-palladin family, peroxisome pro- 
	
conducting at least one gene expression analyses of said 
	
liferator-activated receptors (PPARA), Platelet Derived 
at least one set of cellular samples; 	 Growth Factor (PDGF) family, reticulocalbin, RUNX 
	
examining and determining an anabolic effect, catabolic 	 runt related transcription factors, signal transducer and 
	
effect, or no effect from the results of said at least one 	 35 	 activator of transcription (STAT) family, SMAD family, 
gene expression analyses; 	 stanniocalcin family, SOD super oxide dismutase fam- 
	
generating at least one conclusion from said step of 
	
ily, syndecan family, tumor necrosis factor (TNF) super 
examining and determining; 	 family, AKT/PKB signaling family, and importin fam- 
	
comparing said at least one conclusion with predeter- 	 ily. 
mined criteria; 	 40 	 2. The method of claim 1, wherein said step of controlling 
	
if said at least one conclusion does not meet said prede- 	 is further comprised of manipulating at least one of the fol- 
	
termined criteria, adjusting said at least one experi- 	 lowing said plurality of tuned predetermined figures of merit: 
	
mental predetermined profile based on said at least 	 said tuned rising slew rate, said tuned rise time, said tuned fall 
	
one conclusion and repeating said steps of providing, 	 time, said tuned frequency, said tuned wavelength, and said 
exposing, conducting, examining and determining, 45 tuned duty cycle. 
generating, and comparing; and 
	
3. The method of claim 1, wherein said at least one set of 
	
if said at least one conclusion does meet said predeter- 	 cellular samples is selected from the group consisting of 
	
mined criteria, selecting said at least one tuned time- 	 human chondrocytes, nucleus pulposus, osteoblasts, osteo- 
	
varying stimulation field comprised of said at least 	 clasts, and osteocytes as well as associated tissue. 
one tuned predetermined profile for a predetermined 50 4. The method of claim 1, wherein said step of examining 
	
tuned exposure time or a plurality of tuned exposure 	 and determining is comprised of: 
time sequences, 	 selecting at least one gene or gene family selected from the 
	
wherein said at least one tuned predetermined profile is com- 	 group consisting of Wnt signaling family, WSP family, 
	
prised of a plurality of tuned predetermined figures of merit 	 forkhead box (FOX) family, sex determining region Y 
	
and is controllable through manipulation of at least one of 	 55 	 (SRY) SOX family, parathyroid hormone (PTH) family, 
	
said plurality of tuned predetermined figures of merit, 	 transforming growth factor (TGF) beta (TGF-(3) super 
	
wherein said plurality of tuned predetermined figures of merit 	 family, latent TGF family (ECM), integrin family (Cell 
	
is comprised of two or more of the following: a tuned B-Field 
	
Sulfur-Based (SUR): ECM), interleukin (IL) family 
	
magnitude, tuned rising slew rate, tuned rise time, tuned 
	 (cellular cytokine response), thrombospodin family 
	
falling slew rate, tuned fall time, tuned frequency, tuned 	 60 	 (COMPS), laminin family, proteoglycan family, 
wavelength, and tuned duty cycle; 	 osteoglycin, collagen family, insulin family, a disinte- 
	
controlling said at least one tuned predetermined profile 	 grin and metalloproteinase (ADAM) family, ADAM 
	
comprised of manipulating said tuned B-Field magni- 	 with thrombospondin motifs (ADAMTS) family, matrix 
	
tude to a first value between about 0.6 G to about 200 G 	 metallopeptidase (MMP) family, actin family, catenin 
	
and said tuned falling slew rate to a second value 	 65 	 family, cadherin super family, B-cell lymphoma (BCL) 
	
between about 2.0 kG/s and about 500.0 kG/s thereby 	 family, calmodulin calcium-modulated gene, calume- 
	
resulting in a controlled at least one tuned time-varying 	 nin, cathepsin family, clusterin, cytochrome P 450 super 
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family, endoglin, fibrillin family, fibroblast growth fac-
tor (FGF) family, leptin, MAP kinase activated protein 
kinases (MAPKAP) family, MSX homeobox family, 
NOTCH family, myotilin-myopalladin-palladin family, 
peroxisome proliferator-activated receptors (PPARA), 
Platelet Derived Growth Factor (PDGF) family, reticu-
localbin, RUNX runt related transcription factors, signal 
transducer and activator of transcription (STAT) family, 
SMAD family, stanniocalcin family, SOD super oxide 
dismutase family, syndecan family, tumor necrosis fac-
tor (TNF) super family, AKT/PKB signaling family, and 
importin family; 
calculating a fold change for each gene in said selected at 
least one gene or gene family from the results of said at 
least one gene expression analyses; and 
classifying each of said fold change as said anabolic effect, 
catabolic effect, or no effect. 
5. The method of claim 4, wherein said step of generating 
is comprised of: 
establishing a relative value for each of said anabolic effect 
or catabolic effect; 
comparing each of said relative value in combination; and 
selecting at least one conclusion comprised of either a 
substantive net anabolic effect, a substantive net cata- 
bolic effect, or no determinative effect. 
6. The method of claim 1, wherein said step of exposing is 
comprised of: 
providing a stimulation field generator apparatus capable 
of generating said controlled at least one tuned time-
varying stimulation field and located in proximate spa-
tial relationship to said mammalian chondrocytes, 
osteoblasts, osteocytes, osteoclasts, nucleus pulposus, 
associated tissue, or any combination thereof; and 
generating said controlled at least one tuned time-varying 
stimulation field through operation of said stimulation 
field generator apparatus. 
7. The method of claim 6, wherein said stimulation field 
generator apparatus is comprised of: 
• power source; 
• control component operably connected to said power 
source; and 
• transmission component operably connected to said con-
trol component and said power source, wherein in said 
step of providing a stimulation field generator apparatus 
in proximate spatial relationship to said mammalian 
chondrocytes, osteoblasts, osteocytes, osteoclasts, 
nucleus pulposus, associated tissue, or any combination 
thereof, said transmission component is in proximate 
spatial relationship to said mammalian chondrocytes, 
osteoblasts, osteocytes, osteoclasts, nucleus pulposus, 
associated tissue, or any combination thereof. 
8. The method of claim 1, wherein said first value is 
between about 0.6 G to about 50 G and wherein said step of 
controlling is further comprised of manipulating said rising 
slew rate having a third value between about 2.0 kG/s and 
about 50.0 kG/s. 
9. The method of claim 1, wherein said first value is 
between about 0.6 G to about 50 G and wherein said step of 
controlling is further comprised of manipulating said rising 
slew rate having a third value between about 2.5 kG/s and 
about 15.5 kG/s. 
10. The method of claim 9, wherein said first value is about 
0.65 G and said at least one tuned predetermined profile is 
comprised of substantially a square wave. 
11. The method of claim 1, wherein said first value is 
between about 0.6 G to about 100 G. 
50 
12. The method of claim 11, wherein second value is 
between about 2.5 kG/s and about 15.5 kG/s. 
13. The method of claim 1, wherein said first value is 
between about 0.6 G to about 100 G and wherein said step of 
5 controlling is further comprised of manipulating said tuned 
duty cycle having a fourth value between about 65% to about 
80%. 
14. The method of claim 1, wherein said step of controlling 
is further comprised of manipulating said tuned frequency 
io having a fifth value between about 9 Hz to about 200 Hz. 
15. The method of claim 14, wherein said fifth value is 
between about 10 Hz to about 16 Hz. 
16. The method of claim 1, wherein said predetermined 
tuned exposure time is from about 1 hourto about 1200 hours. 
15 	 17. The method of claim 1, 
wherein said first value is about 0.65 G, and said second 
value is between about 4.5 kG/s to about 15.5 kG/s, and 
wherein said step of controlling is further comprised of 
manipulating: 
20 	 said tuned frequency having a fifth value between about 
10 Hz to about 16 Hz, 
said tuned wavelength having a sixth value between 
about 250 ms to about 600 ms, and 
said tuned duty cycle having a fourth value between 
25 	 about 65% to about 80%. 
18. A method to modulate an increase, decrease, or both 
increase and decrease in the expression level of at least one 
gene or gene family comprising the steps of: 
tuning at least one predetermined profile of at least one 
30 time-varying stimulation field thereby resulting in at 
least one tuned time-varying stimulation field comprised 
of at least one tuned predetermined profile, wherein said 
at least one tuned predetermined profile is comprised of 
a plurality of tuned predetermined figures of merit and is 
35 controllable through manipulation of at least one of said 
plurality of tuned predetermined figures of merit, 
wherein said plurality of tuned predetermined figures of 
merit is comprised of two or more of the following: a 
tuned B-Field magnitude, tuned rising slew rate, tuned 
40 	 rise time, tuned falling slew rate, tuned fall time, tuned 
frequency, tuned wavelength, and tuned duty cycle; 
controlling said at least one tuned predetermined profile 
comprised of manipulating, 
said tuned B-Field magnitude having a first value of 
45 	 about 0.65 G, 
said tuned falling slew rate having a second value 
between about 4.5 kG/s to about 15.5 kG/s, 
said tuned rising slew rate having a third value between 
about 2.0 kG/s and to about 4.5 kG/s, 
50 	 said tuned frequency having a fifth value between about 
10 Hz to about 200 Hz, 
said tuned wavelength having a sixth value of about 500 
ms, 
said tuned duty cycle having a fourth value between 
55 about 65% to about 80%, thereby resulting in a con-
trolled at least one tuned time-varying stimulation 
field comprised of a controlled at least one tuned 
predetermined profile; and 
exposing mammalian chondrocytes, osteoblasts, osteo- 
60 cytes, osteoclasts, nucleus pulposus, associated tissue, 
or any combination thereof to said controlled at least one 
tuned time-varying stimulation field comprised of said 
controlled at least one tuned predetermined profile for a 
tuned exposure time of about 720 hours thereby result- 
65 ing in said increase, decrease, or both increase and 
decrease in the expression level of at least one gene or 
gene family selected from the group consisting of Wnt 
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signaling family, WSP family, forkhead box (FOX) fam-
ily, sex determining region Y (SRY) SOX family, par-
athyroid hormone (PTH) family, transforming growth 
factor (TGF) beta (TGF-(3) super family, latent TGF 
family (ECM), integrin family (Cell Sulfur-Based 
(SUR): ECM), interleukin (IL) family (cellular cytokine 
response), thrombospodin family (COMPS), laminin 
family, proteoglycan family, osteoglycin, collagen fam-
ily, insulin family, a disintegrin and metalloproteinase 
(ADAM) family. ADAM with thrombospondin motifs 
(ADAMTS) family, matrix metallopeptidase (MMP) 
family, actin family, catenin family, cadherin super fam-
ily, B-cell lymphoma (BCL) family, calmodulin cal-
cium-modulated gene, calumenin, cathepsin family, 
clusterin, cytochrome P 450 super family, endoglin, 
fibrillin family, fibroblast growth factor (FGF) family, 
leptin, MAP kinase activated protein kinases (MAP-
KAP) family, MSX homeobox family, NOTCH family, 
myotilin-myopalladin-palladin family, peroxisome pro-
liferator-activated receptors (PPARA), Platelet Derived 
Growth Factor (PDGF) family, reticulocalbin, RUNX 
runt related transcription factors, signal transducer and 
activator of transcription (STAT) family, SMAD family, 
stanniocalcin family, SOD super oxide dismutase fam-
ily, syndecan family, tumor necrosis factor (TNF) super 
family, AKT/PKB signaling family, and importin fam-
ily. 
19. A method to modulate an increase, decrease, or both 
increase and decrease in the expression level of at least one 
gene or gene family comprising the steps of: 
tuning at least one predetermined profile of at least one 
time-varying stimulation field thereby resulting in at 
least one tuned time-varying stimulation field comprised 
of at least one tuned predetermined profile, wherein said 
at least one tuned predetermined profile is comprised of 
a plurality of tuned predetermined figures of merit and is 
controllable through manipulation of at least one of said 
plurality of tuned predetermined figures of merit, 
wherein said plurality of tuned predetermined figures of 
merit is comprised of two or more of the following: a 
tuned B-Field magnitude, tuned rising slew rate, tuned 
rise time, tuned falling slew rate, tuned fall time, tuned 
frequency, tuned wavelength, and tuned duty cycle; 
controlling said at least one tuned predetermined profile 
comprised of manipulating said tuned B-Field magni-
tude to a first value between about 0.6 G to about 200 G 
and said tuned falling slew rate to a second value 
between about 2.0 kG/s and about 500.0 kG/s thereby 
resulting in a controlled at least one tuned time-varying 
stimulation field comprised of a controlled at least one 
tuned predetermined profile; 
exposing mammalian chondrocytes, osteoblasts, osteo- 
5 cytes, osteoclasts, nucleus pulposus, associated tissue, 
or any combination thereof to said controlled at least one 
tuned time-varying stimulation field comprised of said 
controlled at least one tuned predetermined profile for a 
predetermined tuned exposure time or plurality of tuned 
10 exposure time sequences thereby resulting in said 
increase, decrease, or both increase and decrease in the 
expression level of at least one gene or gene family 
selected from the group consisting of Writ signaling 
family, WSP family, forkhead box (FOX) family, sex 
15 determining region Y (SRY) SOX family, parathyroid 
hormone (PTH) family, transforming growth factor 
(TGF) beta (TGF-(3) super family, latent TGF family 
(ECM), integrin family (Cell Sulfur-Based (SUR): 
ECM), interleukin (IL) family (cellular cytokine 
20 response), thrombospodin family (COMPS), laminin 
family, proteoglycan family, osteoglycin, collagen fam-
ily, insulin family, a disintegrin and metalloproteinase 
(ADAM) family, ADAM with thrombospondin motifs 
(ADAMTS) family, matrix metallopeptidase (MMP) 
25 family, actin family, catenin family, cadherin super fam-
ily, B-cell lymphoma (BCL) family, calmodulin cal-
cium-modulated gene, calumenin, cathepsin family, 
clusterin, cytochrome P 450 super family, endoglin, 
fibrillin family, fibroblast growth factor (FGF) family, 
30 leptin, MAP kinase activated protein kinases (MAP-
KAP) family, MSX homeobox family, NOTCH family, 
myotilin-myopalladin-palladin family, peroxisome pro-
liferator-activated receptors (PPARA), Platelet Derived 
Growth Factor (PDGF) family, reticulocalbin, RUNX 
35 runt related transcription factors, signal transducer and 
activator of transcription (STAT) family, SMAD family, 
stanniocalcin family, SOD super oxide dismutase fam-
ily, syndecan family, tumor necrosis factor (TNF) super 
family, AKTIPKB signaling family, and importin fam- 
40 ily, wherein said mammalian chondrocytes, osteoblasts, 
osteocytes, osteoclasts, nucleus pulposus, associatedtis-
sue, or any combination thereof are localized in a pre-
determined region of interest; and introducing Vitamin 
D, Vitamin K, or both to said region of interest. 
45 	 20. The method of claim 1, further comprising the step of 
adding a predetermined amplification factor of predeter- 
mined value to said tuned B-Field magnitude. 
